<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="1c01a9c8-0256-4129-adc7-38d1f3cf2183"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>These highlights do not include all the information needed to use PIPERACILLIN and TAZOBACTAM FOR INJECTION safely and effectively. See full prescribing information for PIPERACILLIN and TAZOBACTAM FOR INJECTION. <br/>
      <br/>PIPERACILLIN and TAZOBACTAM, for Injection, for intravenous use, pharmacy bulk bottles.<br/>
      <br/>Initial U.S. Approval: 1993</title>
   <effectiveTime value="20250226"/>
   <setId root="68d5384d-1691-4afc-8a1a-488f8e2ef2c5"/>
   <versionNumber value="7"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id extension="086861066" root="1.3.6.1.4.1.519.1"/>
            <name>Provepharm Inc.</name>
            <assignedEntity>
               <assignedOrganization/>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="11c798c2-1704-4538-a947-cea7ae02ef00"/>
               <code code="48780-1" displayName="SPL PRODUCT DATA ELEMENTS SECTION" codeSystem="2.16.840.1.113883.6.1"/>
               <title/>
               <text/>
               <effectiveTime value="20230828"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="81284-154" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Piperacillin and Tazobactam</name>
                        <formCode code="C42957" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Piperacillin sodium and Tazobactam sodium</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIM">
                           <quantity>
                              <numerator unit="g" value="12"/>
                              <denominator unit="mL" value="60"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="M98T69Q7HP" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>PIPERACILLIN SODIUM</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="9I628532GX" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>PIPERACILLIN ANHYDROUS</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="ACTIM">
                           <quantity>
                              <numerator unit="g" value="1.5"/>
                              <denominator unit="mL" value="60"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="UXA545ABTT" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TAZOBACTAM SODIUM</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="SE10G96M8W" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>TAZOBACTAM</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="mL" value="60"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="81284-154-00" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43212" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="VIAL, PHARMACY BULK PACKAGE"/>
                              <asContent>
                                 <quantity>
                                    <numerator value="1" unit="1"/>
                                    <denominator value="1" unit="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="81284-154-01" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" displayName="CARTON" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20230111"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" displayName="Type 0: Not a Combination Product" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20230111"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA207848" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38276" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INTRAVENOUS"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="81284-155" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Piperacillin and Tazobactam</name>
                        <formCode code="C42957" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Piperacillin sodium and Tazobactam sodium</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIM">
                           <quantity>
                              <numerator unit="g" value="36"/>
                              <denominator unit="mL" value="180"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="M98T69Q7HP" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>PIPERACILLIN SODIUM</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="9I628532GX" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>PIPERACILLIN ANHYDROUS</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="ACTIM">
                           <quantity>
                              <numerator unit="g" value="4.5"/>
                              <denominator unit="mL" value="180"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="UXA545ABTT" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TAZOBACTAM SODIUM</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="SE10G96M8W" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>TAZOBACTAM</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="mL" value="180"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="81284-155-00" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43212" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="VIAL, PHARMACY BULK PACKAGE"/>
                              <asContent>
                                 <quantity>
                                    <numerator unit="1" value="1"/>
                                    <denominator unit="1" value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code codeSystem="2.16.840.1.113883.6.69" code="81284-155-01"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20190801"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" displayName="Type 0: Not a Combination Product" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20190801"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA207848" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38276" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INTRAVENOUS"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="_fd27eb22-7e29-c1d1-6c39-1f12baeafceb">
               <id root="df6eb056-b455-461a-a2cf-12385f89cf55"/>
               <code code="43683-2" displayName="RECENT MAJOR CHANGES SECTION" codeSystem="2.16.840.1.113883.6.1"/>
               <effectiveTime value="20241231"/>
               <excerpt>
                  <highlight>
                     <text>
                        <table width="100%">
                           <tbody>
                              <tr>
                                 <td>Warnings and Precautions, Rhabdomyolysis (<linkHtml href="#L0db061f4-0386-4d2b-9bd5-5705f03d63d6">5.4</linkHtml>)</td>
                                 <td align="right">09/2024</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph/>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="L681195c2-ddba-4eda-8ecb-231846de81e2">
               <id root="91112584-da29-496f-b5fb-462fce65e467"/>
               <code code="34066-1" displayName="BOXED WARNING SECTION" codeSystem="2.16.840.1.113883.6.1"/>
               <title/>
               <text>
                  <paragraph>
                     <content styleCode="bold">PHARMACY BULK PACKAGE – NOT FOR DIRECT INFUSION</content>
                     <br/>
                  </paragraph>
               </text>
               <effectiveTime value="20221031"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>PHARMACY BULK PACKAGE – NOT FOR DIRECT INFUSION</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="L1ed3ac46-8cd0-4988-bcc1-29d228daaa62">
               <id root="468d8a42-138d-4756-abe2-eb96ee43f5b3"/>
               <code code="34067-9" displayName="INDICATIONS &amp; USAGE SECTION" codeSystem="2.16.840.1.113883.6.1"/>
               <title>1 INDICATIONS AND USAGE</title>
               <text>
                  <paragraph/>
               </text>
               <effectiveTime value="20221031"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Piperacillin and tazobactam for injection is a combination of piperacillin, a penicillin-class antibacterial and tazobactam, a beta-lactamase inhibitor, indicated for treatment of: <br/>
                        </paragraph>
                        <list>
                           <item>Intra-abdominal infections in adult and pediatric patients 2 months of age and older (<linkHtml href="#L678de7cb-f58c-45a2-80f0-b7ee6b961614">1.1</linkHtml>)</item>
                           <item>Nosocomial pneumonia in adult and pediatric patients 2 months of age and older (<linkHtml href="#L39db0530-8440-4c48-a052-03fac22cc54e">1.2</linkHtml>)</item>
                           <item>Skin and skin structure infections in adults (<linkHtml href="#Lb79f9323-21f7-4297-bdc5-e2d6a7c0a092">1.3</linkHtml>)</item>
                           <item>Female pelvic infections in adults (<linkHtml href="#Lecda638a-886c-44b0-9643-e214e2edf609">1.4</linkHtml>)</item>
                           <item>Community-acquired pneumonia in adults (<linkHtml href="#L37159674-ce05-4d1f-a3b9-a044e0daf79a">1.5</linkHtml>)<br/>
                           </item>
                        </list>
                        <paragraph>To reduce the development of drug-resistant bacteria and maintain the effectiveness of piperacillin and tazobactam for injection and other antibacterial drugs, piperacillin and tazobactam for injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. (<linkHtml href="#L782d4d91-4df2-4ca0-95b1-f43e081e4758">1.6</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="L678de7cb-f58c-45a2-80f0-b7ee6b961614">
                     <id root="761a749a-6d62-49e3-a0ca-cba834b259e0"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>1.1 Intra-abdominal Infections</title>
                     <text>
                        <paragraph>Piperacillin and tazobactam for injection is indicated in adults and pediatric patients (2 months of age and older) for the treatment of appendicitis (complicated by rupture or abscess) and peritonitis caused by beta-lactamase producing isolates of <content styleCode="italics">Escherichia coli</content> or the following members of the <content styleCode="italics">Bacteroides fragilis</content> group: <content styleCode="italics">B. fragilis</content>, <content styleCode="italics">B. ovatus</content>, <content styleCode="italics">B. thetaiotaomicron</content>, or <content styleCode="italics">B. vulgatus</content>.</paragraph>
                     </text>
                     <effectiveTime value="20221031"/>
                  </section>
               </component>
               <component>
                  <section ID="L39db0530-8440-4c48-a052-03fac22cc54e">
                     <id root="fbe825ec-a533-4f48-a0a5-a2a5a6e502fa"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>1.2 Nosocomial Pneumonia</title>
                     <text>
                        <paragraph>Piperacillin and tazobactam for injection is indicated in adults and pediatric patients (2 months of age and older) for the treatment of nosocomial pneumonia (moderate to severe) caused by beta lactamase producing isolates of <content styleCode="italics">Staphylococcus aureus</content> and by piperacillin/tazobactam-susceptible <content styleCode="italics">Acinetobacter baumannii</content>, <content styleCode="italics">Haemophilus influenzae</content>, <content styleCode="italics">Klebsiella pneumoniae</content>, and <content styleCode="italics">Pseudomonas aeruginosa</content> (Nosocomial pneumonia caused by <content styleCode="italics">P. aeruginosa</content> should be treated in combination with an aminoglycoside)<content styleCode="italics"> [see Dosage and Administration (<linkHtml href="#Lf51ec41a-7f6c-4408-91f8-7f88e197eae3">2</linkHtml>)]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20221031"/>
                  </section>
               </component>
               <component>
                  <section ID="Lb79f9323-21f7-4297-bdc5-e2d6a7c0a092">
                     <id root="6ad1616f-3c19-4c9b-918a-f4961881ae6c"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>1.3 Skin and Skin Structure Infections</title>
                     <text>
                        <paragraph>Piperacillin and tazobactam for injection is indicated in adults for the treatment of uncomplicated and complicated skin and skin structure infections, including cellulitis, cutaneous abscesses and ischemic/diabetic foot infections caused by beta-lactamase producing isolates of <content styleCode="italics">Staphylococcus aureus</content>.</paragraph>
                     </text>
                     <effectiveTime value="20221028"/>
                  </section>
               </component>
               <component>
                  <section ID="Lecda638a-886c-44b0-9643-e214e2edf609">
                     <id root="6063423d-b642-4a42-a8ec-738d3df86419"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>1.4 Female Pelvic Infections</title>
                     <text>
                        <paragraph>Piperacillin and tazobactam for injection is indicated in adults for the treatment of postpartum endometritis or pelvic inflammatory disease caused by beta-lactamase producing isolates of <content styleCode="italics">Escherichia coli</content>.</paragraph>
                     </text>
                     <effectiveTime value="20221031"/>
                  </section>
               </component>
               <component>
                  <section ID="L37159674-ce05-4d1f-a3b9-a044e0daf79a">
                     <id root="2cebbccd-8575-4010-bd08-68c8c223ee04"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>1.5 Community-acquired Pneumonia</title>
                     <text>
                        <paragraph>Piperacillin and tazobactam for injection is indicated in adults for the treatment of community-acquired pneumonia (moderate severity only) caused by beta-lactamase producing isolates of <content styleCode="italics">Haemophilus influenzae</content>.</paragraph>
                     </text>
                     <effectiveTime value="20221031"/>
                  </section>
               </component>
               <component>
                  <section ID="L782d4d91-4df2-4ca0-95b1-f43e081e4758">
                     <id root="96080f32-da55-4fcd-8efe-7feb6f337bf5"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>1.6 Usage</title>
                     <text>
                        <paragraph>To reduce the development of drug-resistant bacteria and maintain the effectiveness of piperacillin and tazobactam for injection and other antibacterial drugs, piperacillin and tazobactam for injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.</paragraph>
                     </text>
                     <effectiveTime value="20221031"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="Lf51ec41a-7f6c-4408-91f8-7f88e197eae3">
               <id root="54b20c49-f813-4b81-aee6-8404e2055e4a"/>
               <code code="34068-7" displayName="DOSAGE &amp; ADMINISTRATION SECTION" codeSystem="2.16.840.1.113883.6.1"/>
               <title>2 DOSAGE AND ADMINISTRATION</title>
               <text>
                  <paragraph/>
               </text>
               <effectiveTime value="20241231"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>
                              <content styleCode="italics">Adult Patients With Indications Other Than Nosocomial Pneumonia;</content> The usual daily dosage of piperacillin and tazobactam for injection for adults is 3.375 g every six hours totaling 13.5 g (12.0 g piperacillin/1.5 g tazobactam). (<linkHtml href="#L3505a8d1-6670-4862-95d9-0f4993210b75">2.2</linkHtml>)</item>
                           <item>
                              <content styleCode="italics">Adult Patients With Nosocomial Pneumonia: </content>Initial presumptive treatment of patients with nosocomial pneumonia should start with piperacillin and tazobactam for injection at a dosage of 4.5 g every six hours plus an aminoglycoside, totaling 18.0 g (16.0 g piperacillin/2.0 g tazobactam). (<linkHtml href="#L71db5a0f-c2f9-4673-860b-93af35342b99">2.3</linkHtml>)</item>
                           <item>
                              <content styleCode="italics">Adult Patients With Renal Impairment:</content> Dosage in patients with renal impairment (creatinine clearance ≤40 mL/min) and dialysis patients should be reduced, based on the degree of renal impairment. (<linkHtml href="#Lb8df0a7d-5f7b-4c3a-b25a-be8f0cd669eb">2.4</linkHtml>)</item>
                           <item>
                              <content styleCode="italics">Pediatric Patients by Indication and Age:</content> See Table below (<linkHtml href="#Labff894d-8ec7-447a-bfd2-3962bc9ac718">2.5</linkHtml>)</item>
                        </list>
                        <table width="75%" border="Toprule, Botrule, Lrule, Rrule">
                           <tbody>
                              <tr>
                                 <th colspan="3" align="center">
                                    <content styleCode="bold">Recommended Dosage of Piperacillin and Tazobactam for Injection for Pediatric Patients 2 months of Age and Older,Weighing up to 40 Kg and With Normal Renal Function</content>
                                 </th>
                              </tr>
                              <tr>
                                 <td align="center">
                                    <content styleCode="bold">Age </content>
                                 </td>
                                 <td align="center">
                                    <content styleCode="bold">Appendicitis and/or Peritonitis</content>
                                 </td>
                                 <td align="center">
                                    <content styleCode="bold">Nosocomial Pneumonia</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center">
                                    <content styleCode="bold"> 2 months to 9 months </content>
                                 </td>
                                 <td>90 mg/kg (80 mg piperacillin/10 mg tazobactam) <content styleCode="underline">every 8 </content>
                                    <content styleCode="Italics Underline">(eight)</content>
                                    <content styleCode="underline"> hours</content>
                                 </td>
                                 <td>90 mg/kg (80 mg piperacillin/10 mg tazobactam) <content styleCode="underline">every 6 </content>
                                    <content styleCode="Italics Underline">(six)</content>
                                    <content styleCode="underline"> hours</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center">
                                    <content styleCode="bold"> Older<br/> than 9 months </content>
                                 </td>
                                 <td>112.5 mg/kg (100 mg piperacillin/12.5 mg tazobactam) <content styleCode="underline">every 8 </content>
                                    <content styleCode="Italics Underline">(eight)</content>
                                    <content styleCode="underline"> hours</content>
                                 </td>
                                 <td>112.5 mg/kg (100 mg piperacillin/12.5 mg tazobactam) <content styleCode="underline">every 6 </content>
                                    <content styleCode="Italics Underline">(six)</content>
                                    <content styleCode="underline"> hours</content>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <list listType="unordered">
                           <item>Administer piperacillin and tazobactam for injection by intravenous infusion over 30 minutes to both adult and pediatric patients (<linkHtml href="#L3505a8d1-6670-4862-95d9-0f4993210b75">2.2</linkHtml>, <linkHtml href="#Lb8df0a7d-5f7b-4c3a-b25a-be8f0cd669eb">2.3</linkHtml>, <linkHtml href="#Lb8df0a7d-5f7b-4c3a-b25a-be8f0cd669eb">2.4</linkHtml>, <linkHtml href="#Labff894d-8ec7-447a-bfd2-3962bc9ac718">2.5</linkHtml>).</item>
                           <item>Piperacillin and tazobactam for injection and aminoglycosides should be reconstituted, diluted, and administered separately. Co-administration via Y-site can be done under certain conditions. (<linkHtml href="#L00a0291b-0156-449b-9010-44ee58df6dfa">2.8</linkHtml>).</item>
                           <item>See the full prescribing information for the preparation and administration instructions for piperacillin and tazobactam for injection pharmacy bulk bottles.</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="L3505a8d1-6670-4862-95d9-0f4993210b75">
                     <id root="65f36356-3fc6-4e55-81be-ddfabf4d89d2"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>2.2 Dosage in Adult Patients With Indications Other Than Nosocomial Pneumonia</title>
                     <text>
                        <paragraph>The usual total daily dosage of piperacillin and tazobactam for injection for adult patients with indications other than nosocomial pneumonia is 3.375 g every six hours [totaling 13.5 g (12.0 g piperacillin/1.5 g tazobactam)], to be administered by intravenous infusion over 30 minutes. The usual duration of piperacillin and tazobactam for injection treatment is from 7 to 10 days.</paragraph>
                     </text>
                     <effectiveTime value="20221031"/>
                  </section>
               </component>
               <component>
                  <section ID="L71db5a0f-c2f9-4673-860b-93af35342b99">
                     <id root="dd1a2f42-cfc6-4a59-9d64-e9451edc9f0f"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>2.3 Dosage in Adult Patients With Nosocomial Pneumonia</title>
                     <text>
                        <paragraph>Initial presumptive treatment of adult patients with nosocomial pneumonia should start with piperacillin and tazobactam for injection at a dosage of 4.5 g every six hours plus an aminoglycoside, [totaling 18.0 g (16.0 g piperacillin/2.0 g tazobactam)], administered by intravenous infusion over 30 minutes. The recommended duration of piperacillin and tazobactam for injection treatment for nosocomial pneumonia is 7 to 14 days. Treatment with the aminoglycoside should be continued in patients from whom <content styleCode="italics">P. aeruginosa</content> is isolated.</paragraph>
                     </text>
                     <effectiveTime value="20221031"/>
                  </section>
               </component>
               <component>
                  <section ID="Lb8df0a7d-5f7b-4c3a-b25a-be8f0cd669eb">
                     <id root="85b12255-083b-4f8d-9d8b-6fd20b6a353a"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>2.4 Dosage in Adult Patients With Renal Impairment</title>
                     <text>
                        <paragraph>In adult patients with renal impairment (creatinine clearance ≤ 40 mL/min) and dialysis patients (hemodialysis and CAPD), the intravenous dose of piperacillin and tazobactam for injection should be reduced based on the degree of renal impairment. The recommended daily dosage of piperacillin and tazobactam for injection for patients with renal impairment administered by intravenous infusion over 30 minutes is described in Table 1:</paragraph>
                        <table width="75%">
                           <tbody align="center">
                              <tr align="center">
                                 <th colspan="3" align="center">Table 1: Recommended Dosing of Piperacillin and Tazobactam for Injection in Patients with Normal Renal Function and Renal Impairment (As total grams piperacillin/tazobactam)<sup>#</sup>
                                 </th>
                              </tr>
                              <tr>
                                 <td>
                                    <content styleCode="bold">Creatinine clearance, <br/>mL/min</content>
                                 </td>
                                 <td>
                                    <content styleCode="bold">All Indications <br/>(except nosocomial pneumonia)</content>
                                 </td>
                                 <td>
                                    <content styleCode="bold">Nosocomial Pneumonia</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td>Greater than 40 mL/min</td>
                                 <td> 3.375 every 6 hours</td>
                                 <td>4.5 every 6 hours</td>
                              </tr>
                              <tr>
                                 <td>20 to 40 mL/min<sup> * </sup>
                                 </td>
                                 <td> 2.25 every 6 hours</td>
                                 <td>3.375 every 6 hours</td>
                              </tr>
                              <tr>
                                 <td> Less than 20 mL/min<sup> * </sup>
                                 </td>
                                 <td> 2.25 every 8 hours</td>
                                 <td> 2.25 every 6 hours</td>
                              </tr>
                              <tr>
                                 <td>Hemodialysis<sup> ** </sup>
                                 </td>
                                 <td>2.25 every 12 hours</td>
                                 <td>2.25 every 8 hours</td>
                              </tr>
                              <tr>
                                 <td>CAPD</td>
                                 <td>2.25 every 12 hours</td>
                                 <td> 2.25 every 8 hours</td>
                              </tr>
                              <tr>
                                 <td colspan="3" align="left">
                                    <paragraph>
                                       <sup>#</sup> Administer piperacillin and tazobactam for injection by intravenous infusion over 30 minutes.</paragraph>
                                    <paragraph>
                                       <sup>*</sup> Creatinine clearance for patients not receiving hemodialysis<br/>
                                       <sup>**</sup> 0.75 g (0.67 g piperacillin/0.08 g tazobactam) should be administered following each hemodialysis session on hemodialysis days</paragraph>
                                    <paragraph/>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>For patients on hemodialysis, the maximum dose is 2.25 g every twelve hours for all indications other than nosocomial pneumonia and 2.25 g every eight hours for nosocomial pneumonia. Since hemodialysis removes 30% to 40% of the administered dose, an additional dose of 0.75 g piperacillin and tazobactam for injection (0.67 g piperacillin/0.08 g tazobactam) should be administered following each dialysis period on hemodialysis days. No additional dosage of piperacillin and tazobactam for injection is necessary for CAPD patients.</paragraph>
                     </text>
                     <effectiveTime value="20221031"/>
                  </section>
               </component>
               <component>
                  <section ID="Labff894d-8ec7-447a-bfd2-3962bc9ac718">
                     <id root="0cc71d63-f82b-4c9a-81ec-744953012e20"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>2.5 Dosage in Pediatric Patients With Appendicitis/Peritonitis or Nosocomial Pneumonia</title>
                     <text>
                        <paragraph>The recommended dosage for pediatric patients with appendicitis and/or peritonitis or nosocomial pneumonia aged 2 months of age and older, weighing up to 40 kg, and with normal renal function, is described in Table 2 <content styleCode="italics">[</content>
                           <content styleCode="italics">see Use in Specific Populations (<linkHtml href="#L2e9efc5b-ded1-4664-b00c-d42c5d9726df">8.4</linkHtml>)</content> and <content styleCode="italics">Clinical Pharmacology (<linkHtml href="##Lb0d6c39a-97ee-45b4-9283-8e911262fe45">12.3</linkHtml>)</content>
                           <content styleCode="italics">]</content>.
                        </paragraph>
                        <table width="75%">
                           <tbody align="center">
                              <tr>
                                 <td colspan="3">
                                    <content styleCode="bold">Table 2: Recommended Dosage of Piperacillin and Tazobactam for Injection in Pediatric<br/> Patients 2 Months of Age and Older, Weighing Up to 40 kg, and With Normal Renal Function<sup>#</sup>
                                    </content>
                                 </td>
                              </tr>
                              <tr>
                                 <td>
                                    <content styleCode="bold">Age</content>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule Toprule">
                                    <content styleCode="bold">Appendicitis and/or Peritonitis</content>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule Toprule">
                                    <content styleCode="bold">Nosocomial Pneumonia</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td>2 months<br/> to<br/> 9 months</td>
                                 <td>90 mg/kg<br/>(80 mg piperacillin/10 mg tazobactam)<br/>
                                    <content styleCode="underline"> every 8 (</content>
                                    <content styleCode="Italics Underline">eight</content>
                                    <content styleCode="underline">) hours</content>
                                 </td>
                                 <td>90 mg/kg<br/>(80 mg piperacillin/10 mg tazobactam)<br/>
                                    <content styleCode="underline"> every 6 (</content>
                                    <content styleCode="Italics Underline">six</content>
                                    <content styleCode="underline">) hours</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td>Older than<br/> 9 months of age</td>
                                 <td>112.5 mg/kg<br/> (100 mg piperacillin/12.5 mg tazobactam)<br/>
                                    <content styleCode="underline"> every 8 (</content>
                                    <content styleCode="Italics Underline">eight</content>
                                    <content styleCode="underline">) hours</content>
                                 </td>
                                 <td>112.5 mg/kg<br/> (100 mg piperacillin/12.5 mg tazobactam)<br/>
                                    <content styleCode="underline"> every 6 (</content>
                                    <content styleCode="Italics Underline">six</content>
                                    <content styleCode="underline">) hours</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td colspan="3" align="left">
                                    <sup>#</sup>Administer piperacillin and tazobactam for injection by intravenous infusion over 30 minutes</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>Pediatric patients weighing over 40 kg and with normal renal function should receive the adult dose <content styleCode="italics">[</content>
                           <content styleCode="italics">see Dosage and Administration (<linkHtml href="#L3505a8d1-6670-4862-95d9-0f4993210b75">2.2</linkHtml>, <linkHtml href="#L71db5a0f-c2f9-4673-860b-93af35342b99">2.3</linkHtml>)</content>
                           <content styleCode="italics">]</content>.</paragraph>
                        <paragraph>Dosage of piperacillin and tazobactam for injection in pediatric patients with renal impairment has not been determined.</paragraph>
                     </text>
                     <effectiveTime value="20221031"/>
                  </section>
               </component>
               <component>
                  <section ID="L35fcab54-76a2-4e07-a1e6-aa470ad89f03">
                     <id root="a2f23dc1-983a-4adc-a1cd-76b60fcd4c69"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>2.6 Reconstitution and Dilution of Piperacillin and Tazobactam for injection</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Reconstitution of piperacillin and tazobactam for injection for Adult Patients and Pediatric Patients Weighing Over 40 kg</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">Pharmacy bulk bottles</content>
                        </paragraph>
                        <paragraph>Reconstituted stock solution must be transferred and further diluted for intravenous infusion.</paragraph>
                        <paragraph>The pharmacy bulk bottle is for use in a hospital pharmacy admixture service only under a laminar flow hood. After reconstitution, entry into the bottle must be made with a sterile transfer set or other sterile dispensing device, and contents should be dispensed as aliquots into intravenous solution using aseptic technique. Use entire contents of pharmacy bulk bottle promptly. Discard unused portion after 24 hours if stored at room temperature (20°C to 25°C [68°F to 77°F]), or after 48 hours if stored at refrigerated temperature (2°C to 8°C [36°F to 46°F]).</paragraph>
                        <paragraph>Reconstitute the pharmacy bulk bottle with exactly 51mL (for 13.5 g bottle) and 152 mL (for 40.5 bottle) of a compatible reconstitution diluent, listed below, to a concentration of 200 mg/mL of piperacillin and 25 mg/mL of tazobactam. Shake well until dissolved. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to and during administration whenever solution and container permit.</paragraph>
                        <paragraph>
                           <content styleCode="underline">
                              <content styleCode="italics">Compatible Reconstitution Diluents for Pharmacy Bulk Bottles</content>
                           </content>
                        </paragraph>
                        <paragraph>0.9% sodium chloride for injection<br/>Sterile water for injection<br/>Dextrose 5%<br/>Bacteriostatic Saline/Parabens<br/>Bacteriostatic Water/Parabens<br/>Bacteriostatic Saline/Benzyl Alcohol<br/>Bacteriostatic Water/Benzyl Alcohol</paragraph>
                        <paragraph>
                           <content styleCode="underline">Dilution of the Reconstituted piperacillin and tazobactam for injection solution for Adult Patients and Pediatric Patients Weighing Over 40 kg</content>
                        </paragraph>
                        <paragraph>Reconstituted piperacillin and tazobactam for injection solutions for pharmacy bulk bottles should be further diluted (recommended volume per dose of 50 mL to 150 mL) in a compatible intravenous solution listed below. Administer by infusion over a period of at least 30 minutes. During the infusion it is desirable to discontinue the primary infusion solution.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Compatible Intravenous Solutions for Pharmacy Bulk Bottles</content>
                        </paragraph>
                        <paragraph>0.9% sodium chloride for injection<br/>Sterile water for injection (Maximum recommended volume per dose of sterile water for injection is 50 mL)<br/>Dextran 6% in Saline<br/>Dextrose 5%</paragraph>
                        <paragraph>LACTATED RINGER'S SOLUTION IS NOT COMPATIBLE WITH PIPERACILLIN AND TAZOBACTAM FOR INJECTION.
                        </paragraph>
                        <paragraph>Piperacillin and tazobactam for injection should not be mixed with other drugs in a syringe or infusion bottle since compatibility has not been established.</paragraph>
                        <paragraph>Piperacillin and tazobactam for injection is not chemically stable in solutions that contain only sodium bicarbonate and solutions that significantly alter the pH.</paragraph>
                        <paragraph>Piperacillin and tazobactam for injection should not be added to blood products or albumin hydrolysates. Parenteral drug products should be inspected visually for particulate matter or discoloration prior to administration, whenever solution and container permit.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Dilution of the Reconstituted piperacillin and tazobactam for injection for Pediatric Patients Weighing up to 40 kg</content>
                        </paragraph>
                        <paragraph>The volume of reconstituted solution required to deliver the dose of piperacillin and tazobactam for injection is dependent on the weight of the child <content styleCode="italics">[see Dosage and Administration (<linkHtml href="#Labff894d-8ec7-447a-bfd2-3962bc9ac718">2.5</linkHtml>)]</content>. Reconstituted piperacillin and tazobactam for injection solutions for pharmacy bulk bottles should be further diluted in a compatible intravenous solution listed above.</paragraph>
                        <paragraph>1. Calculate patient dose as described in Table 2 above <content styleCode="italics">[see Dosage and Administration (<linkHtml href="#Labff894d-8ec7-447a-bfd2-3962bc9ac718">2.5</linkHtml>)]</content>.</paragraph>
                        <paragraph>2. Reconstitute vial with a compatible reconstitution diluent, as listed above under the subheading "Compatible Reconstitution Diluents for Pharmacy Bulk Bottles and Single-Dose Vials," using the appropriate volume of diluent, as listed in table 3 below. Following the addition of the diluent, shake the pharmacy bulk bottles until the powder is completely dissolved.</paragraph>
                        <table width="100%">
                           <caption> Table 3: Reconstitution of Pharmacy Bulk Vial and Resulting Concentration </caption>
                           <tbody>
                              <tr>
                                 <td align="center">
                                    <content styleCode="underline">
                                       <content styleCode="bold"> Strength per Pharmacy Bulk Bottles</content>
                                    </content>
                                 </td>
                                 <td align="center">
                                    <content styleCode="underline">
                                       <content styleCode="bold"> Volume of Diluent to be Added to the Vial</content>
                                    </content>
                                 </td>
                                 <td align="center">
                                    <content styleCode="underline">
                                       <content styleCode="bold"> Concentration of the Reconstituted Product</content>
                                    </content>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center"> 13.5 g (12 g piperacillin<br/>/1.5 g tazobactam)</td>
                                 <td align="center"> 51 mL</td>
                                 <td align="center"> 225 mg/mL<paragraph>(200 mg/mL piperacillin/<br/>25 mg/mL tazobactam)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center"> 40.5 g (36 g piperacillin<br/>/4.5 g tazobactam)</td>
                                 <td align="center"> 152 mL</td>
                                 <td align="center"> 225 mg/mL<paragraph>(200 mg/mL piperacillin/<br/>25 mg/mL tazobactam)</paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>3. Calculate the required volume (mL) of reconstituted piperacillin and tazobactam for injection solution based on the required dose.</paragraph>
                        <paragraph>4. Aseptically withdraw the required volume of reconstituted piperacillin and tazobactam for injection solution from the pharmacy bulk bottles. It should be further diluted to a final piperacillin concentration of between 20 mg/mL to 80 mg/mL (tazobactam between 2.5 mg/mL to 10 mg/mL) in a compatible intravenous solution (as listed above) in an appropriately sized syringe or IV bag.</paragraph>
                        <paragraph>5. Administer the diluted piperacillin and tazobactam for injection solution by infusion over a period of at least 30 minutes (a programmable syringe or infusion pump is recommended). During the infusion it is desirable to discontinue the primary infusion solution.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Stability of Piperacillin and Tazobactam for Injection Following Reconstitution and Dilution</content>
                        </paragraph>
                        <paragraph>Piperacillin and tazobactam for injection reconstituted from pharmacy bulk bottles is stable in glass and plastic containers (plastic syringes, IV bags and tubing) when used with compatible diluents. The pharmacy bulk bottles should <content styleCode="bold">NOT</content> be frozen after reconstitution. </paragraph>
                        <paragraph>Pharmacy bulk bottles should be used immediately after reconstitution. Discard any unused portion after storage for 24 hours at room temperature (20°C to 25°C [68°F to 77°F]), or after storage for 48 hours at refrigerated temperature (2°C to 8°C [36°F to 46°F]). </paragraph>
                        <paragraph>Stability studies in the IV bags have demonstrated chemical stability (potency, pH of reconstituted solution and clarity of solution) for up to 24 hours at room temperature and up to one week at refrigerated temperature. Piperacillin and tazobactam for injection contains no preservatives. Appropriate consideration of aseptic technique should be used.</paragraph>
                        <paragraph>Piperacillin and tazobactam for injection reconstituted from pharmacy bulk bottles can be used in ambulatory intravenous infusion pumps. Stability of piperacillin and tazobactam for injection in an ambulatory intravenous infusion pump has been demonstrated for a period of 12 hours at room temperature. Each dose was reconstituted and diluted to a volume of 37.5 mL or 25 mL. One-day supply of dosing solution were aseptically transferred into the medication reservoir (IV bags or cartridge). The reservoir was fitted to a preprogrammed ambulatory intravenous infusion pump per the manufacturer's instructions. Stability of piperacillin and tazobactam for injection is not affected when administered using an ambulatory intravenous infusion pump.</paragraph>
                     </text>
                     <effectiveTime value="20221031"/>
                  </section>
               </component>
               <component>
                  <section ID="L00a0291b-0156-449b-9010-44ee58df6dfa">
                     <id root="f149fb1e-502d-4e99-9222-fa777d1e502a"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>2.8 Compatibility with Aminoglycosides</title>
                     <text>
                        <paragraph>Due to the in vitro inactivation of aminoglycosides by piperacillin, piperacillin and tazobactam for injection and aminoglycosides are recommended for separate administration. Piperacillin and tazobactam for injection and aminoglycosides should be reconstituted, diluted, and administered separately when concomitant therapy with aminoglycosides is indicated <content styleCode="italics">[see Drug Interactions (<linkHtml href="#L28ac4a89-85f0-4de1-bc5c-2bd90c607709">7.1</linkHtml>)]</content>.</paragraph>
                        <paragraph>In circumstances where co-administration via Y-site is necessary, piperacillin and tazobactam for injection is compatible for simultaneous co-administration via Y-site infusion only with the following aminoglycosides under the following conditions:</paragraph>
                        <table width="100%">
                           <caption>Table 4: Compatibility with Aminoglycosides </caption>
                           <colgroup>
                              <col width="20%"/>
                              <col width="20%"/>
                              <col width="20%"/>
                              <col width="20%"/>
                              <col width="20%"/>
                           </colgroup>
                           <tfoot>
                              <tr styleCode="First Last">
                                 <td colspan="5">
                                    <sup>a</sup> Diluent volumes apply only to bulk pharmacy containers.<br/>
                                    <sup>b</sup> The concentration ranges in Table 4 are based on administration of the aminoglycoside in divided doses (10-15 mg/kg/day in two daily doses for amikacin and 3-5 mg/kg/day in three daily doses for gentamicin).Administration of amikacin or gentamicin in a single daily dose or in doses exceeding those stated above via Y-site with piperacillin and tazobactam for injection has not been evaluated. See package insert for each aminoglycoside for complete Dosage and Administration instructions.</td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr>
                                 <td align="center"> Aminoglycoside</td>
                                 <td align="center"> Piperacillin and Tazobactam for Injection Dose (grams)</td>
                                 <td align="center"> Piperacillin and Tazobactam for Injection Diluent Volume<sup>a</sup> (mL)</td>
                                 <td align="center">Aminoglycoside Concentration Range<sup>b</sup> (mg/mL) </td>
                                 <td align="center">Acceptable Diluents </td>
                              </tr>
                              <tr>
                                 <td align="center"> Amikacin</td>
                                 <td align="center">2.25<br/>3.375<br/>4.5</td>
                                 <td align="center"> 50<br/>100<br/>150</td>
                                 <td align="center"> 1.75 - 7.5</td>
                                 <td align="center"> 0.9% sodium chloride or 5% dextrose</td>
                              </tr>
                              <tr>
                                 <td align="center"> Gentamicin</td>
                                 <td align="center">2.25<br/>3.375<br/>4.5</td>
                                 <td align="center"> 50<br/>100<br/>150</td>
                                 <td align="center"> 0.7 - 3.32</td>
                                 <td align="center"> 0.9% sodium chloride or 5% dextrose</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>Only the concentration and diluents for amikacin or gentamicin with the dosages of piperacillin and tazobactam for injection listed above have been established as compatible for co administration via Y-site infusion. Simultaneous co-administration via Y-site infusion in any manner other than listed above may result in inactivation of the aminoglycoside by piperacillin and tazobactam for injection.</paragraph>
                        <paragraph>Piperacillin and tazobactam for injection is not compatible with tobramycin for simultaneous co administration via Y-site infusion. Compatibility of piperacillin and tazobactam for injection with other aminoglycosides has not been established.</paragraph>
                        <paragraph>Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.</paragraph>
                     </text>
                     <effectiveTime value="20221031"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="L26130aa8-6c11-4009-b200-1c727e33ae94">
               <id root="4d45684a-a249-4171-b913-66a385121703"/>
               <code code="43678-2" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION" codeSystem="2.16.840.1.113883.6.1"/>
               <title>3 DOSAGE FORMS AND STRENGTHS</title>
               <text>
                  <paragraph>Piperacillin and Tazobactam for Injection is supplied as a white to off-white powder in bottles of the following sizes:</paragraph>
                  <paragraph>Each Piperacillin and Tazobactam for Injection 13.5 g pharmacy bulk bottle provides piperacillin sodium equivalent to 12 grams of piperacillin and tazobactam sodium equivalent to 1.5 g of tazobactam.</paragraph>
                  <paragraph>
                     <content>Each Piperacillin and Tazobactam for Injection 40.5 g pharmacy bulk bottle provides piperacillin sodium equivalent to 36 grams of piperacillin and tazobactam sodium equivalent to 4.5 grams of tazobactam.</content>
                  </paragraph>
               </text>
               <effectiveTime value="20221031"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Piperacillin and Tazobactam for Injection: 13.5 g and 40.5 g lyophilized powder for reconstitution in pharmacy bulk bottles. (<linkHtml href="#L26130aa8-6c11-4009-b200-1c727e33ae94">3</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="L8f709ed8-9263-4332-a0a3-5cf5d5ab871b">
               <id root="819fa93f-ec13-448b-9063-edb7d31fc642"/>
               <code code="34070-3" displayName="CONTRAINDICATIONS SECTION" codeSystem="2.16.840.1.113883.6.1"/>
               <title>4 CONTRAINDICATIONS</title>
               <text>
                  <paragraph>Piperacillin and tazobactam for injection is contraindicated in patients with a history of allergic reactions to any of the penicillins, cephalosporins, or beta-lactamase inhibitors.</paragraph>
               </text>
               <effectiveTime value="20221031"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Patients with a history of allergic reactions to any of the penicillins, cephalosporins, or beta-lactamase inhibitors. (<linkHtml href="#L8f709ed8-9263-4332-a0a3-5cf5d5ab871b">4</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="L94a68a22-74ca-4ee2-b26e-1ed49734666a">
               <id root="e6729950-98fa-473f-b687-ce53fe5fe94d"/>
               <code code="43685-7" displayName="WARNINGS AND PRECAUTIONS SECTION" codeSystem="2.16.840.1.113883.6.1"/>
               <title>5 WARNINGS AND PRECAUTIONS</title>
               <text/>
               <effectiveTime value="20241231"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>Serious hypersensitivity reactions (anaphylactic/anaphylactoid) reactions have been reported in patients receiving piperacillin and tazobactam for injection. Discontinue piperacillin and tazobactam for injection if a reaction occurs. (<linkHtml href="#La26915fc-510e-430f-af28-e9c6d2540746">5.1</linkHtml>)</item>
                           <item>Piperacillin and tazobactam for injection may cause severe cutaneous adverse reactions, such as Stevens-Johnson syndrome, toxic epidermal necrolysis, drug reaction with eosinophilia and systemic symptoms, and acute generalized exanthematous pustulosis. Discontinue piperacillin and tazobactam for injection for progressive rashes. (<linkHtml href="#L4324d4bb-273f-49fb-ba18-f3c3de384515">5.2</linkHtml>)</item>
                           <item>Hemophagocytic lymphohistiocytosis (HLH) has been reported with the use of piperacillin and tazobactam for injection. If HLH is suspected, discontinue piperacillin and tazobactam for injection immediately. (<linkHtml href="#Lb38164a3-89ff-4552-a153-71e46e87cd5b">5.3</linkHtml>)</item>
                           <item>Rhabdomyolysis: If signs or symptoms of rhabdomyolysis are observed, discontinue Piperacillin and tazobactam for injection and initiate appropriate therapy. (<linkHtml href="#L0db061f4-0386-4d2b-9bd5-5705f03d63d6">5.4</linkHtml>)</item>
                           <item>Hematological effects (including bleeding, leukopenia and neutropenia) have occurred. Monitor hematologic tests during prolonged therapy. (<linkHtml href="#L8638bcfd-2da4-4b12-b705-8c79d3a18df9">5.5</linkHtml>)</item>
                           <item>As with other penicillins, piperacillin and tazobactam for injection may cause neuromuscular excitability or seizures. Patients receiving higher doses, especially in the presence of renal impairment may be at greater risk. Closely monitor patients with renal impairment or seizure disorders for signs and symptoms of neuromuscular excitability or seizures. (<linkHtml href="#L5f3fb929-cf79-4ddb-8a91-af6358448242">5.6</linkHtml>)</item>
                           <item>Nephrotoxicity in critically ill patients has been observed; the use of piperacillin and tazobactam for injection was found to be an independent risk factor for renal failure and was associated with delayed recovery of renal function as compared to other beta-lactam antibacterial drugs in a randomized, multicenter, controlled trial in critically ill patients. Based on this study, alternative treatment options should be considered in the critically ill population. If alternative treatment options are inadequate or unavailable, monitor renal function during treatment with piperacillin and tazobactam for injection. (<linkHtml href="#L2d44f865-e063-4b58-bd09-6de9e65a53e9">5.7</linkHtml>)</item>
                           <item>
                              <content styleCode="italics">Clostridioides difficile</content>-associated diarrhea: evaluate patients if diarrhea occurs. (<linkHtml href="#Lc6a19e90-286b-4ee8-8070-09f051adf5f7">5.9</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="La26915fc-510e-430f-af28-e9c6d2540746">
                     <id root="5e813a05-541f-47c3-a305-28e1fc18f61d"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>5.1 Hypersensitivity Adverse Reactions</title>
                     <text>
                        <paragraph>Serious and occasionally fatal hypersensitivity (anaphylactic/anaphylactoid) reactions (including shock) have been reported in patients receiving therapy with piperacillin and tazobactam for injection. These reactions are more likely to occur in individuals with a history of penicillin, cephalosporin, or carbapenem hypersensitivity or a history of sensitivity to multiple allergens. Before initiating therapy with piperacillin and tazobactam for injection, careful inquiry should be made concerning previous hypersensitivity reactions. If an allergic reaction occurs, piperacillin and tazobactam for injection should be discontinued and appropriate therapy instituted.</paragraph>
                     </text>
                     <effectiveTime value="20240916"/>
                  </section>
               </component>
               <component>
                  <section ID="L4324d4bb-273f-49fb-ba18-f3c3de384515">
                     <id root="6814cef2-2084-408d-af2a-52e6b52fea32"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>5.2 Severe Cutaneous Adverse Reactions</title>
                     <text>
                        <paragraph>Piperacillin and tazobactam for injection may cause severe cutaneous adverse reactions, such as Stevens-Johnson syndrome, toxic epidermal necrolysis, drug reaction with eosinophilia and systemic symptoms, and acute generalized exanthematous pustulosis. If patients develop a skin rash they should be monitored closely and piperacillin and tazobactam for injection discontinued if lesions progress.</paragraph>
                     </text>
                     <effectiveTime value="20221031"/>
                  </section>
               </component>
               <component>
                  <section ID="Lb38164a3-89ff-4552-a153-71e46e87cd5b">
                     <id root="d885d6f5-f159-41c0-ae34-0104ef672052"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>5.3 Hemophagocytic Lymphohistiocytosis</title>
                     <text>
                        <paragraph>Cases of hemophagocytic lymphohistiocytosis (HLH) have been reported in pediatric and adult patients treated with piperacillin and tazobactam for injection. Signs and symptoms of HLH may include fever, rash, lymphadenopathy, hepatosplenomegaly and cytopenia. If HLH is suspected, discontinue piperacillin and tazobactam for injection immediately and institute appropriate management.
                        </paragraph>
                     </text>
                     <effectiveTime value="20240916"/>
                  </section>
               </component>
               <component>
                  <section ID="L0db061f4-0386-4d2b-9bd5-5705f03d63d6">
                     <id root="b5682f57-302f-4e78-be55-310485f20606"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.4 Rhabdomyolysis</title>
                     <text>
                        <paragraph>Rhabdomyolysis has been reported with the use of Piperacillin and tazobactam for injection <content styleCode="italics">[see Adverse Reactions (<linkHtml href="#La995bc3d-7b42-4155-8035-c61792726d03">6.2</linkHtml>)]</content>. If signs or symptoms of rhabdomyolysis such as muscle pain, tenderness or weakness, dark urine, or elevated creatine phosphokinase are observed, discontinue Piperacillin and tazobactam for injection and initiate appropriate therapy.</paragraph>
                     </text>
                     <effectiveTime value="20240916"/>
                  </section>
               </component>
               <component>
                  <section ID="L8638bcfd-2da4-4b12-b705-8c79d3a18df9">
                     <id root="a287b6c3-0899-4ac0-a87d-57f323449b3e"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>5.5 Hematologic Adverse Reactions</title>
                     <text>
                        <paragraph>Bleeding manifestations have occurred in some patients receiving beta-lactam drugs, including piperacillin. These reactions have sometimes been associated with abnormalities of coagulation tests such as clotting time, platelet aggregation and prothrombin time, and are more likely to occur in patients with renal failure. If bleeding manifestations occur, piperacillin and tazobactam for injection should be discontinued and appropriate therapy instituted.</paragraph>
                        <paragraph>The leukopenia/neutropenia associated with piperacillin and tazobactam for injection administration appears to be reversible and most frequently associated with prolonged administration.</paragraph>
                        <paragraph>Periodic assessment of hematopoietic function should be performed, especially with prolonged therapy, i.e., ≥ 21 days <content styleCode="italics">[</content>
                           <content styleCode="italics">see Adverse Reactions (<linkHtml href="#L498ab2fc-3314-4806-a9c6-36cd82e8d482">6.1</linkHtml>)</content>
                           <content styleCode="italics">]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20240916"/>
                  </section>
               </component>
               <component>
                  <section ID="L5f3fb929-cf79-4ddb-8a91-af6358448242">
                     <id root="7178d1b6-115b-4b19-a2ad-b4956c44559e"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>5.6 Central Nervous System Adverse Reactions</title>
                     <text>
                        <paragraph>As with other penicillins, piperacillin and tazobactam for injection may cause neuromuscular excitability or seizures. Patients receiving higher doses, especially patients with renal impairment may be at greater risk for central nervous system adverse reactions. Closely monitor patients with renal impairment or seizure disorders for signs and symptoms of neuromuscular excitability or seizures <content styleCode="italics">[</content>
                           <content styleCode="italics">see Adverse Reactions (<linkHtml href="#La995bc3d-7b42-4155-8035-c61792726d03">6.2</linkHtml>)</content>
                           <content styleCode="italics">]</content>. </paragraph>
                     </text>
                     <effectiveTime value="20240916"/>
                  </section>
               </component>
               <component>
                  <section ID="L2d44f865-e063-4b58-bd09-6de9e65a53e9">
                     <id root="7483180a-bd26-44db-99c6-cdfab61bbf34"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>5.7 Nephrotoxicity in Critically Ill Patients</title>
                     <text>
                        <paragraph>The use of piperacillin and tazobactam for injection was found to be an independent risk factor for renal failure and was associated with delayed recovery of renal function as compared to other beta-lactam antibacterial drugs in a randomized, multicenter, controlled trial in critically ill patients <content styleCode="italics">[</content>
                           <content styleCode="italics">see Adverse Reactions (<linkHtml href="#L498ab2fc-3314-4806-a9c6-36cd82e8d482">6.1</linkHtml>)</content>
                           <content styleCode="italics">]</content>. Based on this study, alternative treatment options should be considered in the critically ill population. If alternative treatment options are inadequate or unavailable, monitor renal function during treatment with piperacillin and tazobactam for injection <content styleCode="italics">[</content>
                           <content styleCode="italics">see Dosage and Administration (<linkHtml href="#Lb8df0a7d-5f7b-4c3a-b25a-be8f0cd669eb">2.4</linkHtml>)</content>
                           <content styleCode="italics">]</content>.</paragraph>
                        <paragraph>Combined use of piperacillin/tazobactam and vancomycin may be associated with an increased incidence of acute kidney injury <content styleCode="italics">[</content>
                           <content styleCode="italics">see Drug Interactions (<linkHtml href="#Lf69a1c9e-d7e6-44ae-8e92-abf49d1135d3">7.3</linkHtml>)</content>
                           <content styleCode="italics">]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20240916"/>
                  </section>
               </component>
               <component>
                  <section ID="L79da843d-2a76-4be9-b886-d9f430a90f94">
                     <id root="4f1eb39a-8973-4089-b554-8a69b8907758"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>5.8 Electrolyte Effects</title>
                     <text>
                        <paragraph>Piperacillin and tazobactam for injection contains a total of 2.84 mEq (65 mg) of Na+ (sodium) per gram of piperacillin in the combination product. This should be considered when treating patients requiring restricted salt intake. Periodic electrolyte determinations should be performed in patients with low potassium reserves, and the possibility of hypokalemia should be kept in mind with patients who have potentially low potassium reserves and who are receiving cytotoxic therapy or diuretics.</paragraph>
                     </text>
                     <effectiveTime value="20240916"/>
                  </section>
               </component>
               <component>
                  <section ID="Lc6a19e90-286b-4ee8-8070-09f051adf5f7">
                     <id root="25f3127d-583a-4570-ab5a-5f668a58ee17"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>5.9<content styleCode="italics"> Clostridioides difficile-</content>Associated <content styleCode="None">Diarrhea</content>
                     </title>
                     <text>
                        <paragraph>
                           <content styleCode="italics">Clostridioides difficile</content>-associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including piperacillin and tazobactam for injection, and may range in severity from mild diarrhea to fatal colitis. Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of <content styleCode="italics">C. difficile</content>.</paragraph>
                        <paragraph>
                           <content styleCode="italics">C. difficile</content> produces toxins A and B which contribute to the development of CDAD. Hypertoxin producing strains of <content styleCode="italics">C. difficile</content> cause increased morbidity and mortality, as these infections can be refractory to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with diarrhea following antibacterial drug use. Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents.</paragraph>
                        <paragraph>If CDAD is suspected or confirmed, ongoing antibacterial drug use not directed against <content styleCode="italics">C. difficile</content> may need to be discontinued. Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of <content styleCode="italics">C. difficile</content>, and surgical evaluation should be instituted as clinically indicated.</paragraph>
                     </text>
                     <effectiveTime value="20240916"/>
                  </section>
               </component>
               <component>
                  <section ID="L6aacc601-ac23-465f-a7cb-027bf1854bc5">
                     <id root="46b11876-029b-44d3-8d75-980591080d06"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>5.10 Development of Drug-Resistant Bacteria</title>
                     <text>
                        <paragraph>Prescribing piperacillin and tazobactam for injection in the absence of a proven or strongly suspected bacterial infection or a prophylactic indication is unlikely to provide benefit to the patient and increases the risk of development of drug-resistant bacteria.</paragraph>
                     </text>
                     <effectiveTime value="20240916"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="Ld9837194-8e16-4ab7-9509-cf0757a4c8aa">
               <id root="9aeefe64-1713-4c5f-9bb0-382bebb5dda6"/>
               <code code="34084-4" displayName="ADVERSE REACTIONS SECTION" codeSystem="2.16.840.1.113883.6.1"/>
               <title>6 ADVERSE REACTIONS</title>
               <text>
                  <paragraph>The following clinically significant adverse reactions are described elsewhere in the labeling:</paragraph>
                  <paragraph>• Hypersensitivity Adverse Reactions <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#La26915fc-510e-430f-af28-e9c6d2540746">5.1</linkHtml>)]</content>
                  </paragraph>
                  <paragraph>• Severe Cutaneous Adverse Reactions <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#L4324d4bb-273f-49fb-ba18-f3c3de384515">5.2</linkHtml>)]</content>
                  </paragraph>
                  <paragraph>• Hemophagocytic Lymphohistiocytosis <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#Lb38164a3-89ff-4552-a153-71e46e87cd5b">5.3</linkHtml>)]</content>
                  </paragraph>
                  <paragraph>• Rhabdomyolysis <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#L0db061f4-0386-4d2b-9bd5-5705f03d63d6">5.4</linkHtml>)]</content>
                  </paragraph>
                  <paragraph>• Hematologic Adverse Reactions <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#L8638bcfd-2da4-4b12-b705-8c79d3a18df9">5.5</linkHtml>)]</content>
                  </paragraph>
                  <paragraph>• Central Nervous System Adverse Reactions <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#L5f3fb929-cf79-4ddb-8a91-af6358448242">5.6</linkHtml>)]</content>
                  </paragraph>
                  <paragraph>• Nephrotoxicity in Critically Ill Patients <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#L2d44f865-e063-4b58-bd09-6de9e65a53e9">5.7</linkHtml>)]</content>
                  </paragraph>
                  <paragraph>• Clostridioides difficile-Associated Diarrhea <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#Lc6a19e90-286b-4ee8-8070-09f051adf5f7">5.9</linkHtml>)]</content>
                  </paragraph>
               </text>
               <effectiveTime value="20240916"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>The most common adverse reactions (incidence &gt;5%) are diarrhea, constipation, nausea, headache, and insomnia. (<linkHtml href="#L498ab2fc-3314-4806-a9c6-36cd82e8d482">6.1</linkHtml>)<br/>
                           <br/>
                           <content styleCode="bold">To report SUSPECTED ADVERSE REACTIONS, contact Provepharm Inc., at 1–833-727-6556 or <content styleCode="underline">safety-us@provepharm.com</content> or FDA at 1-800-FDA-1088 or <content styleCode="underline">www.fda.gov/medwatch</content>
                           </content>.</paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="L498ab2fc-3314-4806-a9c6-36cd82e8d482">
                     <id root="0ea0f9ba-6b52-4b3f-8856-954606921052"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>6.1 Clinical Trials Experience</title>
                     <text>
                        <paragraph>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Clinical Trials in Adult Patients</content>
                           <br/>During the initial clinical investigations, 2621 patients worldwide were treated with piperacillin and tazobactam for injection in phase 3 trials. In the key North American monotherapy clinical trials (n=830 patients), 90% of the adverse events reported were mild to moderate in severity and transient in nature. However, in 3.2% of the patients treated worldwide, piperacillin and tazobactam for injection was discontinued because of adverse events primarily involving the skin (1.3%), including rash and pruritus; the gastrointestinal system (0.9%), including diarrhea, nausea, and vomiting; and allergic reactions (0.5%).</paragraph>
                        <table width="75%">
                           <caption>Table 5: Adverse Reactions from Piperacillin and Tazobactam for Injection Monotherapy Clinical Trials</caption>
                           <tbody>
                              <tr>
                                 <td styleCode="Botrule">
                                    <content styleCode="bold">System Organ Class</content>
                                    <br/>   Adverse Reaction</td>
                              </tr>
                              <tr>
                                 <td>
                                    <paragraph>
                                       <content styleCode="bold">Gastrointestinal disorders</content>
                                       <br/>   Diarrhea (11.3%)<br/>   Constipation (7.7%)<br/>   Nausea (6.9%)<br/>   Vomiting (3.3%)<br/>   Dyspepsia (3.3%)<br/>   Abdominal pain (1.3%)</paragraph>
                                    <paragraph>
                                       <content styleCode="bold">General disorders and administration site conditions</content>
                                       <br/>   Fever (2.4%)<br/>   Injection site reaction (≤1%)<br/>   Rigors (≤1%)</paragraph>
                                    <paragraph>
                                       <content styleCode="bold">Immune system disorders</content>
                                       <br/>   Anaphylaxis (≤1%)  </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">Infections and infestations</content>
                                       <br/>   Candidiasis (1.6%)<br/>   Pseudomembranous colitis (≤1%)</paragraph>
                                    <paragraph>
                                       <content styleCode="bold">Metabolism and nutrition disorders</content>
                                       <br/>   Hypoglycemia (≤1%)</paragraph>
                                    <paragraph>
                                       <content styleCode="bold">Musculoskeletal and connective tissue disorders</content>
                                       <br/>   Myalgia (≤1%)<br/>   Arthralgia (≤1%)</paragraph>
                                    <paragraph>
                                       <content styleCode="bold">Nervous system disorders</content>
                                       <br/>   Headache (7.7%)</paragraph>
                                    <paragraph>
                                       <content styleCode="bold">Psychiatric disorders</content>
                                       <br/>   Insomnia (6.6%)</paragraph>
                                    <paragraph>
                                       <content styleCode="bold">Skin and subcutaneous tissue disorders</content>
                                       <br/>   Rash (4.2%, including maculopapular, bullous, and urticarial)<br/>   Pruritus (3.1%)<br/>   Purpura (≤1%)</paragraph>
                                    <paragraph>
                                       <content styleCode="bold">Vascular disorders</content>
                                       <br/>   Phlebitis (1.3%)<br/>   Thrombophlebitis (≤1%)<br/>   Hypotension (≤1%)<br/>   Flushing (≤1%)</paragraph>
                                    <paragraph>
                                       <content styleCode="bold">Respiratory, thoracic and mediastinal disorders</content>
                                       <br/>   Epistaxis (≤1%)</paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>
                           <content styleCode="underline">Nosocomial Pneumonia Trials</content>
                        </paragraph>
                        <paragraph>Two trials of nosocomial lower respiratory tract infections were conducted. In one study, 222 patients were treated with piperacillin and tazobactam for injection in a dosing regimen of 4.5 g every 6 hours in combination with an aminoglycoside and 215 patients were treated with imipenem/cilastatin (500 mg/500 mg every 6 hours) in combination with an aminoglycoside. In this trial, treatment-emergent adverse events were reported by 402 patients, 204 (91.9%) in the piperacillin/tazobactam group and 198 (92.1%) in the imipenem/cilastatin group. Twenty-five (11.0%) patients in the piperacillin/tazobactam group and 14 (6.5%) in the imipenem/cilastatin group (p &gt; 0.05) discontinued treatment due to an adverse event.</paragraph>
                        <paragraph>The second trial used a dosing regimen of 3.375 g given every 4 hours with an aminoglycoside.</paragraph>
                        <table width="75%">
                           <caption>Table 6: Adverse Reactions from Piperacillin and Tazobactam for Injection Plus Aminoglycoside Clinical Trials<sup>a</sup>
                           </caption>
                           <tfoot>
                              <tr styleCode="First Last">
                                 <td>
                                    <paragraph>
                                       <sup>a</sup> For adverse drug reactions that appeared in both studies the higher frequency is presented.</paragraph>
                                 </td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr>
                                 <td styleCode="Botrule">
                                    <content styleCode="bold">System Organ Class</content>
                                    <br/>   Adverse Reaction</td>
                              </tr>
                              <tr>
                                 <td>
                                    <paragraph>
                                       <content styleCode="bold">Blood and lymphatic system disorders</content>
                                       <br/>   Thrombocythemia (1.4%)<br/>   Anemia (≤1%)<br/>   Thrombocytopenia (≤1%)<br/>   Eosinophilia (≤1%)</paragraph>
                                    <paragraph>
                                       <content styleCode="bold">Gastrointestinal disorders</content>
                                       <br/>   Diarrhea (20%)<br/>   Constipation (8.4%)<br/>   Nausea (5.8%)<br/>   Vomiting (2.7%)<br/>   Dyspepsia (1.9%)<br/>   Abdominal pain (1.8%)<br/>   Stomatitis (≤1%)</paragraph>
                                    <paragraph>
                                       <content styleCode="bold">General disorders and administration site conditions</content>
                                       <br/>   Fever (3.2%)<br/>   Injection site reaction (≤1%)</paragraph>
                                    <paragraph>
                                       <content styleCode="bold">Infections and infestations</content>
                                       <br/>   Oral candidiasis (3.9%)<br/>   Candidiasis (1.8%)</paragraph>
                                    <paragraph>
                                       <content styleCode="bold">Investigations</content>
                                       <br/>   BUN increased (1.8%)<br/>   Blood creatinine increased (1.8%)<br/>   Liver function test abnormal (1.4%)<br/>   Alkaline phosphatase increased (≤1%)<br/>   Aspartate aminotransferase increased (≤1%)<br/>   Alanine aminotransferase increased (≤1%)</paragraph>
                                    <paragraph>
                                       <content styleCode="bold">Metabolism and nutrition disorders</content>
                                       <br/>   Hypoglycemia (≤1%)<br/>   Hypokalemia (≤1%)</paragraph>
                                    <paragraph>
                                       <content styleCode="bold">Nervous System Disorders</content>
                                       <br/>   Headache (4.5%)</paragraph>
                                    <paragraph>
                                       <content styleCode="bold">Psychiatric disorders</content>
                                       <br/>   Insomnia (4.5%)</paragraph>
                                    <paragraph>
                                       <content styleCode="bold">Renal and urinary disorders</content>
                                       <br/>   Renal failure (≤1%)</paragraph>
                                    <paragraph>
                                       <content styleCode="bold">Skin and subcutaneous tissue disorders</content>
                                       <br/>   Rash (3.9%)<br/>   Pruritus (3.2%)</paragraph>
                                    <paragraph>
                                       <content styleCode="bold">Vascular disorders</content>
                                       <br/>   Thrombophlebitis (1.3%)<br/>   Hypotension (1.3%)</paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>
                           <content styleCode="underline">Other trials: Nephrotoxicity</content>
                        </paragraph>
                        <paragraph>In a randomized, multicenter, controlled trial in 1200 adult critically ill patients, piperacillin/tazobactam was found to be a risk factor for renal failure (odds ratio 1.7, 95% CI 1.18 to 2.43), and associated with delayed recovery of renal function as compared to other beta-lactam antibacterial drugs.<sup>1</sup>
                           <content styleCode="italics">[</content>
                           <content styleCode="italics">see Warnings and Precautions (<linkHtml href="#L2d44f865-e063-4b58-bd09-6de9e65a53e9">5.7</linkHtml>)</content>
                           <content styleCode="italics">]</content>.</paragraph>
                        <paragraph>Adverse Laboratory Events (Seen During Clinical Trials)</paragraph>
                        <paragraph>Of the trials reported, including that of nosocomial lower respiratory tract infections in which a higher dose of piperacillin and tazobactam for injection was used in combination with an aminoglycoside, changes in laboratory parameters include:</paragraph>
                        <paragraph>
                           <content styleCode="italics">Hematologic</content> – decreases in hemoglobin and hematocrit, thrombocytopenia, increases in platelet count, eosinophilia, leukopenia, neutropenia. These patients were withdrawn from therapy; some had accompanying systemic symptoms (e.g., fever, rigors, chills).</paragraph>
                        <paragraph>
                           <content styleCode="italics">Coagulation</content> – positive direct Coombs' test, prolonged prothrombin time, prolonged partial thromboplastin time</paragraph>
                        <paragraph>
                           <content styleCode="italics">Hepatic</content> – transient elevations of AST (SGOT), ALT (SGPT), alkaline phosphatase, bilirubin</paragraph>
                        <paragraph>
                           <content styleCode="italics">Renal</content> – increases in serum creatinine, blood urea nitrogen</paragraph>
                        <paragraph>Additional laboratory events include abnormalities in electrolytes (i.e., increases and decreases in sodium, potassium, and calcium), hyperglycemia, decreases in total protein or albumin, blood glucose decreased, gamma-glutamyltransferase increased, hypokalemia, and bleeding time prolonged.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Clinical Trials in Pediatri</content>
                           <content styleCode="underline">c Patients</content>
                        </paragraph>
                        <paragraph>Clinical studies of piperacillin and tazobactam for injection in pediatric patients suggest a similar safety profile to that seen in adults.</paragraph>
                        <paragraph>In a prospective, randomized, comparative, open-label clinical trial of pediatric patients, 2 to 12 years of age, with intra-abdominal infections (including appendicitis and/or peritonitis), 273 patients were treated with piperacillin and tazobactam for injection 112.5 mg/kg given IV every 8 hours and 269 patients were treated with cefotaxime (50 mg/kg) plus metronidazole (7.5 mg/kg) every 8 hours. In this trial, treatment-emergent adverse events were reported by 146 patients, 73 (26.7%) in the piperacillin and tazobactam for injection group and 73 (27.1%) in the cefotaxime/metronidazole group. Six patients (2.2%) in the piperacillin and tazobactam for injection group and 5 patients (1.9%) in the cefotaxime/metronidazole group discontinued due to an adverse event.</paragraph>
                        <paragraph>In a retrospective, cohort study, 140 pediatric patients 2 months to less than 18 years of age with nosocomial pneumonia were treated with piperacillin and tazobactam for injection and 267 patients were treated with comparators (which included ticarcillin-clavulanate, carbapenems, ceftazidime, cefepime, or ciprofloxacin). The rates of serious adverse reactions were generally similar between the piperacillin and tazobactam for injection and comparator groups, including patients aged 2 months to 9 months treated with piperacillin and tazobactam for injection 90 mg/kg IV every 6 hours and patients older than 9 months and less than 18 years of age treated with piperacillin and tazobactam for injection 112.5 mg/kg IV every 6 hours.</paragraph>
                     </text>
                     <effectiveTime value="20240916"/>
                  </section>
               </component>
               <component>
                  <section ID="La995bc3d-7b42-4155-8035-c61792726d03">
                     <id root="f2804c70-3c38-48ab-af2f-f9ce5bafec35"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>6.2 Postmarketing Experience</title>
                     <text>
                        <paragraph>In addition to the adverse drug reactions identified in clinical trials in Table 4 and Table 5, the following adverse reactions have been identified during post-approval use of piperacillin and tazobactam for injection. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Hepatobiliary</content> – hepatitis, jaundice</paragraph>
                        <paragraph>
                           <content styleCode="italics">Hematologic</content> – hemolytic anemia, agranulocytosis, pancytopenia</paragraph>
                        <paragraph>
                           <content styleCode="italics">Immune</content> – hypersensitivity reactions, anaphylactic/anaphylactoid reactions (including shock), hemophagocytic lymphohistiocytosis (HLH), acute myocardial ischemia with or without myocardial infarction may occur as part of an allergic reaction</paragraph>
                        <paragraph>
                           <content styleCode="italics">Renal</content> – interstitial nephritis</paragraph>
                        <paragraph>
                           <content styleCode="italics">Nervous system disorders</content> – seizures</paragraph>
                        <paragraph>
                           <content styleCode="italics">Psychiatric disorders</content> – delirium</paragraph>
                        <paragraph>
                           <content styleCode="italics">Respiratory</content> – eosinophilic pneumonia</paragraph>
                        <paragraph>
                           <content styleCode="italics">Skin and Appendages</content> – erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis, drug reaction with eosinophilia and systemic symptoms, (DRESS), acute generalized exanthematous pustulosis (AGEP), dermatitis exfoliative, and linear IgA bullous dermatosis</paragraph>
                        <paragraph>
                           <content styleCode="italics">Musculoskeletal</content> – rhabdomyolysis</paragraph>
                        <paragraph>
                           <content>Postmarketing experience with piperacillin and tazobactam for injection in pediatric patients suggests a similar safety profile to that seen in adults.</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20240916"/>
                  </section>
               </component>
               <component>
                  <section ID="L86c2fcef-fdc4-4cd2-a1d3-c6d511c8d72a">
                     <id root="860951f5-209d-41e8-8d33-a955468465dc"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>6.3 Additional Experience with Piperacillin</title>
                     <text>
                        <paragraph>The following adverse reaction has also been reported for piperacillin for injection:</paragraph>
                        <paragraph>
                           <content styleCode="italics">Skeletal</content> – prolonged neuromuscular blockade <content styleCode="italics">[</content>
                           <content styleCode="italics">see Drug Interactions (<linkHtml href="#Lc57551d6-3560-4c4d-a04c-94ef8263c6db">7.5</linkHtml>)</content>
                           <content styleCode="italics">]</content>.</paragraph>
                        <paragraph/>
                     </text>
                     <effectiveTime value="20221031"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="L5ccd0173-4390-452d-b310-7b18e78d7e3c">
               <id root="86771243-4981-4ea3-a162-8ea74748a97b"/>
               <code code="34073-7" displayName="DRUG INTERACTIONS SECTION" codeSystem="2.16.840.1.113883.6.1"/>
               <title>7 DRUG INTERACTIONS</title>
               <text/>
               <effectiveTime value="20240916"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>Piperacillin and tazobactam for injection administration can significantly reduce tobramycin concentrations in hemodialysis patients. Monitor tobramycin concentrations in these patients. (<linkHtml href="#L28ac4a89-85f0-4de1-bc5c-2bd90c607709">7.1</linkHtml>)</item>
                           <item>Probenecid prolongs the half-lives of piperacillin and tazobactam and should not be co-administered with piperacillin and tazobactam for injection unless the benefit outweighs the risk. (<linkHtml href="#L1abad56a-f5c8-485e-ae73-e68144156d2f">7.2</linkHtml>)</item>
                           <item>Co-administration of piperacillin and tazobactam for injection with vancomycin may increase the incidence of acute kidney injury. Monitor kidney function in patients receiving piperacillin and tazobactam for injection and vancomycin. (<linkHtml href="#Lf69a1c9e-d7e6-44ae-8e92-abf49d1135d3">7.3</linkHtml>)</item>
                           <item>Monitor coagulation parameters in patients receiving piperacillin and tazobactam for injection and heparin or oral anticoagulants. (<linkHtml href="#L686568a4-4060-4daf-849c-4ee9da4ce668">7.4</linkHtml>)</item>
                           <item>Piperacillin and tazobactam for injection may prolong the neuromuscular blockade of vecuronium and other non-depolarizing neuromuscular blockers. Monitor for adverse reactions related to neuromuscular blockade. (<linkHtml href="#Lc57551d6-3560-4c4d-a04c-94ef8263c6db">7.5</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="L28ac4a89-85f0-4de1-bc5c-2bd90c607709">
                     <id root="40b203ca-78c6-48f7-9242-36557219729b"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>7.1 Aminoglycosides</title>
                     <text>
                        <paragraph>Piperacillin may inactivate aminoglycosides by converting them to microbiologically inert amides.</paragraph>
                        <paragraph>
                           <content styleCode="underline">In vivo inactivation:</content>
                        </paragraph>
                        <paragraph>When aminoglycosides are administered in conjunction with piperacillin to patients with end-stage renal disease requiring hemodialysis, the concentrations of the aminoglycosides (especially tobramycin) may be significantly reduced and should be monitored.</paragraph>
                        <paragraph>Sequential administration of piperacillin and tazobactam for injection and tobramycin to patients with either normal renal function or mild to moderate renal impairment has been shown to modestly decrease serum concentrations of tobramycin but no dosage adjustment is considered necessary.</paragraph>
                        <paragraph>
                           <content styleCode="underline">In vitro inactivation:</content>
                        </paragraph>
                        <paragraph>Due to the in vitro inactivation of aminoglycosides by piperacillin, piperacillin and tazobactam for injection and aminoglycosides are recommended for separate administration. Piperacillin and tazobactam for injection and aminoglycosides should be reconstituted, diluted, and administered separately when concomitant therapy with aminoglycosides is indicated. Piperacillin and tazobactam for injection is not compatible with tobramycin for simultaneous Y-site infusion <content styleCode="italics">[</content>
                           <content styleCode="italics">see Dosage and Administration (<linkHtml href="#L00a0291b-0156-449b-9010-44ee58df6dfa">2.8</linkHtml>)</content>
                           <content styleCode="italics">]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20240916"/>
                  </section>
               </component>
               <component>
                  <section ID="L1abad56a-f5c8-485e-ae73-e68144156d2f">
                     <id root="9b4187a6-4b90-443b-b88b-44946bd7d1a6"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>7.2 Probenecid</title>
                     <text>
                        <paragraph>Probenecid administered concomitantly with piperacillin and tazobactam for injection prolongs the half-life of piperacillin by 21% and that of tazobactam by 71% because probenecid inhibits tubular renal secretion of both piperacillin and tazobactam. Probenecid should not be co-administered with piperacillin and tazobactam for injection unless the benefit outweighs the risk.</paragraph>
                     </text>
                     <effectiveTime value="20221031"/>
                  </section>
               </component>
               <component>
                  <section ID="Lf69a1c9e-d7e6-44ae-8e92-abf49d1135d3">
                     <id root="27f286b5-5eb1-4822-b196-ef9e332076c2"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>7.3 Vancomycin</title>
                     <text>
                        <paragraph>Studies have detected an increased incidence of acute kidney injury in patients concomitantly administered piperacillin/tazobactam and vancomycin as compared to vancomycin alone <content styleCode="italics">[</content>
                           <content styleCode="italics">see Warnings and Precautions (<linkHtml href="#L2d44f865-e063-4b58-bd09-6de9e65a53e9">5.7</linkHtml>)</content>
                           <content styleCode="italics">]</content>.</paragraph>
                        <paragraph>Monitor kidney function in patients concomitantly administered with piperacillin/tazobactam and vancomycin.</paragraph>
                        <paragraph>No pharmacokinetic interactions have been noted between piperacillin/tazobactam and vancomycin.</paragraph>
                     </text>
                     <effectiveTime value="20240916"/>
                  </section>
               </component>
               <component>
                  <section ID="L686568a4-4060-4daf-849c-4ee9da4ce668">
                     <id root="790fa73f-c3a8-4a96-92d9-a89f675d0830"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>7.4 Anticoagulants</title>
                     <text>
                        <paragraph>Coagulation parameters should be tested more frequently and monitored regularly during simultaneous administration of high doses of heparin, oral anticoagulants, or other drugs that may affect the blood coagulation system or the thrombocyte function <content styleCode="italics">[</content>
                           <content styleCode="italics">see Warnings and Precautions (<linkHtml href="#L8638bcfd-2da4-4b12-b705-8c79d3a18df9">5.5</linkHtml>)</content>
                           <content styleCode="italics">]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20240916"/>
                  </section>
               </component>
               <component>
                  <section ID="Lc57551d6-3560-4c4d-a04c-94ef8263c6db">
                     <id root="b847ab88-b16e-4705-bda2-c2e282dd0e9d"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>7.5 Vecuronium</title>
                     <text>
                        <paragraph>Piperacillin when used concomitantly with vecuronium has been implicated in the prolongation of the neuromuscular blockade of vecuronium. Piperacillin and tazobactam for injection could produce the same phenomenon if given along with vecuronium. Due to their similar mechanism of action, it is expected that the neuromuscular blockade produced by any of the non-depolarizing neuromuscular blockers could be prolonged in the presence of piperacillin. Monitor for adverse reactions related to neuromuscular blockade (see package insert for vecuronium bromide).</paragraph>
                     </text>
                     <effectiveTime value="20221031"/>
                  </section>
               </component>
               <component>
                  <section ID="L50742246-3c9a-475e-b414-018238bf8dda">
                     <id root="f9fd8148-ee1e-472f-b097-748968e8d17a"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>7.6 Methotrexate</title>
                     <text>
                        <paragraph>Limited data suggests that co-administration of methotrexate and piperacillin may reduce the clearance of methotrexate due to competition for renal secretion. The impact of tazobactam on the elimination of methotrexate has not been evaluated. If concurrent therapy is necessary, serum concentrations of methotrexate as well as the signs and symptoms of methotrexate toxicity should be frequently monitored.</paragraph>
                     </text>
                     <effectiveTime value="20221031"/>
                  </section>
               </component>
               <component>
                  <section ID="L5f2fd9d1-bb39-4cdb-a720-3cba51448b82">
                     <id root="e61060ea-3961-4027-8182-9cb0e3458706"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>7.7 Effects on Laboratory Tests</title>
                     <text>
                        <paragraph>There have been reports of positive test results using the Bio-Rad Laboratories Platelia <content styleCode="None">Aspergillus </content>EIA test in patients receiving piperacillin/tazobactam injection who were subsequently found to be free of <content styleCode="italics">Aspergillus</content> infection. Cross-reactions with non-<content styleCode="italics">Aspergillus</content> polysaccharides and polyfuranoses with the Bio-Rad Laboratories Platelia Aspergillus EIA test have been reported. Therefore, positive test results in patients receiving piperacillin/tazobactam should be interpreted cautiously and confirmed by other diagnostic methods.</paragraph>
                        <paragraph>As with other penicillins, the administration of piperacillin and tazobactam for injection may result in a false-positive reaction for glucose in the urine using a copper-reduction method (CLINITEST<sup>®</sup>). It is recommended that glucose tests based on enzymatic glucose oxidase reactions be used.</paragraph>
                     </text>
                     <effectiveTime value="20221031"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="Le68f0793-6f63-4948-854b-dc530077a6b6">
               <id root="925e5035-2313-4c0f-851b-8390a1920d20"/>
               <code code="43684-0" displayName="USE IN SPECIFIC POPULATIONS SECTION" codeSystem="2.16.840.1.113883.6.1"/>
               <title>8 USE IN SPECIFIC POPULATIONS</title>
               <text/>
               <effectiveTime value="20221031"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Dosage in patients with renal impairment (creatinine clearance ≤40 mL/min) should be reduced based on the degree of renal impairment. (<linkHtml href="#Lb8df0a7d-5f7b-4c3a-b25a-be8f0cd669eb">2.4</linkHtml>, <linkHtml href="#La8c9147d-d982-47e0-8cee-e0f38e1538a9">8.6</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="L675a98d8-e68f-43e6-bf1a-09f6eb19ec9c">
                     <id root="0ad76fc9-719c-4d47-b4b5-76bb460a12e7"/>
                     <code code="42228-7" displayName="PREGNANCY SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>8.1 Pregnancy</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Risk Summary</content>
                        </paragraph>
                        <paragraph>Piperacillin and tazobactam cross the placenta in humans. However, there are insufficient data with piperacillin and/or tazobactam in pregnant women to inform a drug-associated risk for major birth defects and miscarriage. No fetal structural abnormalities were observed in rats or mice when piperacillin/tazobactam was administered intravenously during organogenesis at doses 1 to 2 times and 2 to 3 times the human dose of piperacillin and tazobactam, respectively, based on body-surface area (mg/m<sup>2</sup>). However, fetotoxicity in the presence of maternal toxicity was observed in developmental toxicity and peri/postnatal studies conducted in rats (intraperitoneal administration prior to mating and throughout gestation or from gestation day 17 through lactation day 21) at doses less than the maximum recommended human daily dose based on body-surface area (mg/m<sup>2</sup>) [<content styleCode="italics">see Data</content>].</paragraph>
                        <paragraph>The background risk of major birth defects and miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively.<br/>
                        </paragraph>
                        <paragraph>
                           <content styleCode="underline">Data</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Animal Data</content>
                        </paragraph>
                        <paragraph>In embryo-fetal development studies in mice and rats, pregnant animals received intravenous doses of piperacillin/tazobactam up to 3000/750 mg/kg/day during the period of organogenesis. There was no evidence of teratogenicity up to the highest dose evaluated, which is 1 to 2 times and 2 to 3 times the human dose of piperacillin and tazobactam, in mice and rats respectively, based on body-surface area (mg/m<sup>2</sup>). Fetal body weights were reduced in rats at maternally toxic doses at or above 500/62.5 mg/kg/day, minimally representing 0.4 times the human dose of both piperacillin and tazobactam based on body-surface area (mg/m<sup>2</sup>).</paragraph>
                        <paragraph>A fertility and general reproduction study in rats using intraperitoneal administration of tazobactam or the combination piperacillin/tazobactam prior to mating and through the end of gestation, reported a decrease in litter size in the presence of maternal toxicity at 640 mg/kg/day tazobactam (4 times the human dose of tazobactam based on body-surface area), and decreased litter size and an increase in fetuses with ossification delays and variations of ribs, concurrent with maternal toxicity at ≥640/160 mg/kg/day piperacillin/tazobactam (0.5 times and 1 times the human dose of piperacillin and tazobactam, respectively, based on body-surface area).</paragraph>
                        <paragraph>Peri/postnatal development in rats was impaired with reduced pup weights, increased stillbirths, and increased pup mortality concurrent with maternal toxicity after intraperitoneal administration of tazobactam alone at doses ≥320 mg/kg/day (2 times the human dose based on body surface area) or of the combination piperacillin/tazobactam at doses ≥640/160 mg/kg/day (0.5 times and 1 times the human dose of piperacillin and tazobactam, respectively, based on body-surface area) from gestation day 17 through lactation day 21.</paragraph>
                        <paragraph/>
                     </text>
                     <effectiveTime value="20221031"/>
                  </section>
               </component>
               <component>
                  <section ID="Lcd8c05dc-f3ca-44e4-b3a7-5d572c30da75">
                     <id root="86de3d06-940b-4a16-bdad-90cb82e8a3c7"/>
                     <code code="77290-5" codeSystem="2.16.840.1.113883.6.1" displayName="LACTATION SECTION"/>
                     <title>8.2 Lactation</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline"> Risk Summary</content>
                        </paragraph>
                        <paragraph>Piperacillin is excreted in human milk; tazobactam concentrations in human milk have not been studied. No information is available on the effects of piperacillin and tazobactam on the breastfed child or on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for piperacillin and tazobactam for injection and any potential adverse effects on the breastfed child from piperacillin and tazobactam for injection or from the underlying maternal condition.</paragraph>
                     </text>
                     <effectiveTime value="20221031"/>
                  </section>
               </component>
               <component>
                  <section ID="L2e9efc5b-ded1-4664-b00c-d42c5d9726df">
                     <id root="b941366e-7f11-4f5a-bc1b-cd96d25669e1"/>
                     <code code="34081-0" displayName="PEDIATRIC USE SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>8.4 Pediatric Use</title>
                     <text>
                        <paragraph>The safety and effectiveness of piperacillin and tazobactam for injection for intra-abdominal infections, and nosocomial pneumonia have been established in pediatric patients 2 months of age and older.</paragraph>
                        <paragraph>Use of piperacillin and tazobactam for injection in pediatric patients 2 months of age and older with intra-abdominal infections including appendicitis and/or peritonitis is supported by evidence from well-controlled studies and pharmacokinetic studies in adults and in pediatric patients. This includes a prospective, randomized, comparative, open-label clinical trial with 542 pediatric patients 2 to 12 years of age with intra-abdominal infections (including appendicitis and/or peritonitis), in which 273 pediatric patients received piperacillin/tazobactam <content styleCode="italics">[</content>
                           <content styleCode="italics">see Adverse Reactions (<linkHtml href="#L498ab2fc-3314-4806-a9c6-36cd82e8d482">6.1</linkHtml>)</content>
                           <content styleCode="None"> and </content>
                           <content styleCode="italics">Clinical Pharmacology (<linkHtml href="#Lb0d6c39a-97ee-45b4-9283-8e911262fe45">12.3</linkHtml>)]</content>.</paragraph>
                        <paragraph>Use of piperacillin and tazobactam for injection in pediatric patients 2 months of age and older with nosocomial pneumonia is supported by evidence from well-controlled studies in adults with nosocomial pneumonia, a simulation study performed with a population pharmacokinetic model, and a retrospective, cohort study of pediatric patients with nosocomial pneumonia in which 140 pediatric patients were treated with piperacillin and tazobactam for injection and 267 patients treated with comparators (which included ticarcillin-clavulanate, carbapenems, ceftazidime, cefepime, or ciprofloxacin) <content styleCode="italics">
                              <content styleCode="None">[</content>
                           </content>
                           <content styleCode="italics">see Adverse Reactions (<linkHtml href="#L498ab2fc-3314-4806-a9c6-36cd82e8d482">6.1</linkHtml>)</content>
                           <content styleCode="None"> and </content>
                           <content styleCode="italics">Clinical Pharmacology (<linkHtml href="#Lb0d6c39a-97ee-45b4-9283-8e911262fe45">12.3</linkHtml>)</content>
                           <content styleCode="None">
                              <content styleCode="italics">]</content>.</content>
                        </paragraph>
                        <paragraph>The safety and effectiveness of piperacillin and tazobactam for injection have not been established in pediatric patients less than 2 months of age <content styleCode="italics">
                              <content styleCode="None">[</content>
                           </content>
                           <content styleCode="italics">see Clinical Pharmacology (<linkHtml href="#L737f8669-7a99-4e09-a505-4ad4f48e70ba">12</linkHtml>)</content>
                           <content styleCode="None"> and </content>
                           <content styleCode="italics">Dosage and Administration (<linkHtml href="#Lf51ec41a-7f6c-4408-91f8-7f88e197eae3">2</linkHtml>)</content>
                           <content styleCode="None">
                              <content styleCode="italics">]</content>.</content>
                        </paragraph>
                        <paragraph>Dosage of piperacillin and tazobactam for injection in pediatric patients with renal impairment has not been determined.</paragraph>
                     </text>
                     <effectiveTime value="20221031"/>
                  </section>
               </component>
               <component>
                  <section ID="La7b01d5a-addf-4426-915f-46d62bb40f40">
                     <id root="aeca9f0a-61e6-441e-9876-6767b8052ac3"/>
                     <code code="34082-8" displayName="GERIATRIC USE SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>8.5 Geriatric Use</title>
                     <text>
                        <paragraph>Patients over 65 years are not at an increased risk of developing adverse effects solely because of age. However, dosage should be adjusted in the presence of renal impairment <content styleCode="italics">[</content>
                           <content styleCode="italics">see Dosage and Administration (<linkHtml href="#Lf51ec41a-7f6c-4408-91f8-7f88e197eae3">2</linkHtml>)</content>
                           <content styleCode="italics">]</content>.</paragraph>
                        <paragraph>In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.</paragraph>
                        <paragraph>Piperacillin and tazobactam for injection contains 65 mg (2.84 mEq) of sodium per gram of piperacillin in the combination product. At the usual recommended doses, patients would receive between 780 and 1040 mg/day (34.1 and 45.5 mEq) of sodium. The geriatric population may respond with a blunted natriuresis to salt loading. This may be clinically important with regard to such diseases as congestive heart failure.</paragraph>
                        <paragraph>This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function.</paragraph>
                     </text>
                     <effectiveTime value="20191129"/>
                  </section>
               </component>
               <component>
                  <section ID="La8c9147d-d982-47e0-8cee-e0f38e1538a9">
                     <id root="f66ffdff-7df5-4f8a-b3d6-eb571b68883f"/>
                     <code code="88828-9" codeSystem="2.16.840.1.113883.6.1" displayName="RENAL IMPAIRMENT SUBSECTION"/>
                     <title>8.6 Renal Impairment</title>
                     <text>
                        <paragraph>In patients with creatinine clearance ≤ 40 mL/min and dialysis patients (hemodialysis and CAPD), the intravenous dose of piperacillin and tazobactam for injection should be reduced to the degree of renal function impairment <content styleCode="italics">[</content>
                           <content styleCode="italics">see Dosage and Administration (<linkHtml href="#Lf51ec41a-7f6c-4408-91f8-7f88e197eae3">2</linkHtml>)</content>
                           <content styleCode="italics">]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20191206"/>
                  </section>
               </component>
               <component>
                  <section ID="Ld52b7186-7114-434f-98b0-83b3c84ea439">
                     <id root="649e687e-e329-467a-bf6b-a3809cdb443d"/>
                     <code code="88829-7" codeSystem="2.16.840.1.113883.6.1" displayName="HEPATIC IMPAIRMENT SUBSECTION"/>
                     <title>8.7 Hepatic Impairment</title>
                     <text>
                        <paragraph>Dosage adjustment of piperacillin and tazobactam for injection is not warranted in patients with hepatic cirrhosis <content styleCode="italics">[</content>
                           <content styleCode="italics">see Clinical Pharmacology (<linkHtml href="#Lb0d6c39a-97ee-45b4-9283-8e911262fe45">12.3</linkHtml>)</content>
                           <content styleCode="italics">]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20191206"/>
                  </section>
               </component>
               <component>
                  <section ID="Lf206438a-c7b9-4cf1-afb2-dcbac066b62d">
                     <id root="60e7bd21-7318-437d-abfc-4005aababd1a"/>
                     <code code="88829-7" codeSystem="2.16.840.1.113883.6.1" displayName="HEPATIC IMPAIRMENT SUBSECTION"/>
                     <title>8.8 Patients with Cystic Fibrosis</title>
                     <text>
                        <paragraph>As with other semisynthetic penicillins, piperacillin therapy has been associated with an increased incidence of fever and rash in cystic fibrosis patients.</paragraph>
                     </text>
                     <effectiveTime value="20191206"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="L763251a4-ea08-4e46-9c78-4cc5ea48b03f">
               <id root="2202a89d-d499-4a5a-a467-3718ba1f19d7"/>
               <code code="34088-5" displayName="OVERDOSAGE SECTION" codeSystem="2.16.840.1.113883.6.1"/>
               <title>10 OVERDOSAGE</title>
               <text>
                  <paragraph>There have been postmarketing reports of overdose with piperacillin/tazobactam. The majority of those events experienced, including nausea, vomiting, and diarrhea, have also been reported with the usual recommended dosages. Patients may experience neuromuscular excitability or seizures if higher than recommended doses are given intravenously (particularly in the presence of renal failure) <content styleCode="italics">[</content>
                     <content styleCode="italics">see Warnings and Precautions (<linkHtml href="#L5f3fb929-cf79-4ddb-8a91-af6358448242">5.5</linkHtml>)</content>
                     <content styleCode="italics">]</content>.</paragraph>
                  <paragraph>Treatment should be supportive and symptomatic according the patient's clinical presentation. Excessive serum concentrations of either piperacillin or tazobactam may be reduced by hemodialysis. Following a single 3.375 g dose of piperacillin/tazobactam, the percentage of the piperacillin and tazobactam dose removed by hemodialysis was approximately 31% and 39%, respectively <content styleCode="italics">[see Clinical Pharmacology (<linkHtml href="#L737f8669-7a99-4e09-a505-4ad4f48e70ba">12</linkHtml>)]</content>.</paragraph>
               </text>
               <effectiveTime value="20221031"/>
            </section>
         </component>
         <component>
            <section ID="L5b6aaa01-5dd0-466a-b40e-b8ba9fc1e1e7">
               <id root="86c3a5da-9d07-49d5-b491-898f58b14899"/>
               <code code="34089-3" displayName="DESCRIPTION SECTION" codeSystem="2.16.840.1.113883.6.1"/>
               <title>11 DESCRIPTION</title>
               <text>
                  <paragraph>Piperacillin and Tazobactam for Injection is an injectable antibacterial combination product consisting of the semisynthetic antibacterial piperacillin sodium and the beta-lactamase inhibitor tazobactam sodium for intravenous administration.</paragraph>
                  <paragraph>Piperacillin sodium is derived from D(-)-α-aminobenzyl-penicillin. The chemical name of piperacillin sodium is sodium(2<content styleCode="italics">S</content>,5<content styleCode="italics">R</content>,6<content styleCode="italics">R</content>)-6-[(<content styleCode="italics">R</content>)-2-(4-ethyl-2,3-dioxo-1-piperazinecarboxamido)-2-phenylacetamido]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate. The chemical formula is C<sub>23</sub>H<sub>26</sub>N<sub>5</sub>NaO<sub>7</sub>S and the molecular weight is 539.5. The chemical structure of piperacillin sodium is:</paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="Ldd933faa-90be-42f4-948f-6adde2ff0d6e"/>
                  </paragraph>
                  <paragraph>Tazobactam sodium, a derivative of the penicillin nucleus, is a penicillanic acid sulfone. Its chemical name is sodium(2<content styleCode="italics">S</content>,3<content styleCode="italics">S</content>,5<content styleCode="italics">R</content>)-3-methyl-7-oxo-3-(1<content styleCode="italics">H</content>-1,2,3-triazol-1-ylmethyl)-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate-4,4-dioxide. The chemical formula is C<sub>10</sub>H<sub>11</sub>N<sub>4</sub>NaO<sub>5</sub>S and the molecular weight is 322.3. The chemical structure of tazobactam sodium is:</paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="Lac57a78c-8a0e-42fa-bd02-b686e618b8d3"/>
                  </paragraph>
                  <paragraph>Piperacillin and Tazobactam for Injection contains a total of 2.84 mEq (65 mg) of sodium (Na<sup>+</sup>) per gram of piperacillin in the combination product.</paragraph>
                  <paragraph>Piperacillin and Tazobactam for Injection is a white to off-white sterile powder consisting of piperacillin and tazobactam as their sodium salts packaged in a glass bottles.</paragraph>
                  <list listType="unordered">
                     <item>Each Piperacillin and Tazobactam for Injection 13.5 g pharmacy bulk bottle contains piperacillin sodium equivalent to 12 grams of piperacillin and tazobactam sodium equivalent to 1.5 g of tazobactam sufficient for delivery of multiple doses.</item>
                     <item>Each Piperacillin and Tazobactam for Injection 40.5 g pharmacy bulk bottle contains piperacillin sodium equivalent to 36 grams of piperacillin and tazobactam sodium equivalent to 4.5 g of tazobactam sufficient for delivery of multiple doses.</item>
                  </list>
               </text>
               <effectiveTime value="20221031"/>
               <component>
                  <observationMedia ID="Ldd933faa-90be-42f4-948f-6adde2ff0d6e">
                     <text>pip1</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="pip1.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="Lac57a78c-8a0e-42fa-bd02-b686e618b8d3">
                     <text>taz2</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="taz2.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="L737f8669-7a99-4e09-a505-4ad4f48e70ba">
               <id root="3023de06-a5e7-4c9b-a373-35106154f094"/>
               <code code="34090-1" displayName="CLINICAL PHARMACOLOGY SECTION" codeSystem="2.16.840.1.113883.6.1"/>
               <title>12 CLINICAL PHARMACOLOGY</title>
               <text/>
               <effectiveTime value="20240916"/>
               <component>
                  <section ID="Ld415e3ca-1f25-4bf5-a559-7dc93463d47f">
                     <id root="1130c596-949c-4e54-9328-de947a137dee"/>
                     <code code="43679-0" displayName="MECHANISM OF ACTION SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>12.1 Mechanism of Action</title>
                     <text>
                        <paragraph>Piperacillin and tazobactam for injection is an antibacterial drug <content styleCode="italics">[</content>
                           <content styleCode="italics">see Microbiology (<linkHtml href="#L14ab85ab-6125-465b-bc62-4427fb8a23a2">12.4</linkHtml>)</content>
                           <content styleCode="italics">]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20240916"/>
                  </section>
               </component>
               <component>
                  <section ID="Lf35f6253-d477-4f3b-b102-a0eb5695d849">
                     <id root="d8af31d3-33c8-4a1d-84e1-73c4ade06e9e"/>
                     <code code="43681-6" displayName="PHARMACODYNAMICS SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>12.2 Pharmacodynamics</title>
                     <text>
                        <paragraph>The pharmacodynamic parameter for piperacillin/tazobactam that is most predictive of clinical and microbiological efficacy is time above MIC.</paragraph>
                     </text>
                     <effectiveTime value="20221031"/>
                  </section>
               </component>
               <component>
                  <section ID="Lb0d6c39a-97ee-45b4-9283-8e911262fe45">
                     <id root="0a6eec2c-e40e-450a-8d18-0b07519e44da"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>12.3 Pharmacokinetics</title>
                     <text>
                        <paragraph>The mean and coefficients of variation (CV%) for the pharmacokinetic parameters of piperacillin and tazobactam for injection after multiple intravenous doses are summarized in Table 7.</paragraph>
                        <table width="75%">
                           <caption>Table 7: Mean (CV%) Piperacillin and Tazobactam for Injection PK Parameters</caption>
                           <tfoot>
                              <tr styleCode="First Last">
                                 <td colspan="7">
                                    <sup>a</sup> Piperacillin and tazobactam were given in combination, infused over 30 minutes.<br/>
                                    <sup>b</sup> Numbers in [] parentheses are coefficients of variation (CV%)<br/>C<sub>max</sub>: maximum observed concentration, AUC: Area under the curve, CL: clearance, CL<sub>R</sub>: Renal clearance V: volume of distribution, T<sub>1/2</sub>: elimination half-life </td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr>
                                 <td styleCode="Lrule Rrule" colspan="7" align="center">
                                    <content styleCode="bold">  Piperacillin</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Toprule">Piperacillin/Tazobactam<br/> Dose<sup>a</sup>
                                 </td>
                                 <td styleCode="Botrule Toprule" align="center"> C<sub>max</sub>
                                    <paragraph>(mcg/mL)</paragraph>
                                 </td>
                                 <td styleCode="Botrule Toprule" align="center"> AUC<sup>b</sup>
                                    <paragraph>(mcg•h/mL)</paragraph>
                                 </td>
                                 <td styleCode="Botrule Toprule" align="center"> CL<paragraph>(mL/min)</paragraph>
                                 </td>
                                 <td styleCode="Botrule Toprule" align="center">V<paragraph>(L)</paragraph>
                                 </td>
                                 <td styleCode="Botrule Toprule" align="center"> T<sub>1/2</sub>
                                    <paragraph>(h)</paragraph>
                                 </td>
                                 <td styleCode="Botrule Rrule Toprule" align="center"> CL<sub>R</sub>
                                    <paragraph>(mL/min)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule">2.25 g</td>
                                 <td align="center"> 134</td>
                                 <td align="center"> 131 [14]</td>
                                 <td align="center"> 257</td>
                                 <td align="center"> 17.4</td>
                                 <td align="center"> 0.79</td>
                                 <td styleCode="Rrule" align="center"> -</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule">3.375 g</td>
                                 <td align="center"> 242</td>
                                 <td align="center"> 242 [10]</td>
                                 <td align="center"> 207</td>
                                 <td align="center"> 15.1</td>
                                 <td align="center"> 0.84</td>
                                 <td styleCode="Rrule" align="center"> 140</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule">4.5 g</td>
                                 <td align="center"> 298</td>
                                 <td align="center"> 322 [16]</td>
                                 <td align="center"> 210</td>
                                 <td align="center"> 15.4</td>
                                 <td align="center"> 0.84</td>
                                 <td styleCode="Rrule" align="center"> -</td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule" colspan="7" align="center">
                                    <content styleCode="bold">Tazobactam   </content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule">Piperacillin/Tazobactam<br/> Dose<sup>a</sup>
                                 </td>
                                 <td styleCode="Botrule" align="center"> C<sub>max</sub>
                                    <paragraph>(mcg/mL)</paragraph>
                                 </td>
                                 <td styleCode="Botrule" align="center"> AUC<sup>b</sup>
                                    <paragraph>(mcg•h/mL)</paragraph>
                                 </td>
                                 <td styleCode="Botrule" align="center"> CL<paragraph>(mL/min)</paragraph>
                                 </td>
                                 <td styleCode="Botrule" align="center">V<paragraph>(L)</paragraph>
                                 </td>
                                 <td styleCode="Botrule" align="center"> T<sub>1/2</sub>
                                    <paragraph>(h)</paragraph>
                                 </td>
                                 <td styleCode="Botrule Rrule" align="center"> CL<sub>R</sub>
                                    <paragraph>(mL/min)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule">2.25 g</td>
                                 <td align="center"> 15</td>
                                 <td align="center"> 16.0 [21]</td>
                                 <td align="center"> 258</td>
                                 <td align="center"> 17.0</td>
                                 <td align="center"> 0.77</td>
                                 <td styleCode="Rrule" align="center"> -</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule">3.375 g</td>
                                 <td align="center"> 24</td>
                                 <td align="center"> 25.0 [8]</td>
                                 <td align="center"> 251</td>
                                 <td align="center"> 14.8</td>
                                 <td align="center"> 0.68</td>
                                 <td styleCode="Rrule" align="center"> 166</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule">4.5 g</td>
                                 <td align="center"> 34</td>
                                 <td align="center"> 39.8 [15]</td>
                                 <td align="center"> 206</td>
                                 <td align="center"> 14.7</td>
                                 <td align="center"> 0.82</td>
                                 <td styleCode="Rrule" align="center"> -</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>Peak plasma concentrations of piperacillin and tazobactam are attained immediately after completion of an intravenous infusion of piperacillin and tazobactam for injection. Piperacillin plasma concentrations, following a 30-minute infusion of piperacillin and tazobactam for injection, were similar to those attained when equivalent doses of piperacillin were administered alone. Steady-state plasma concentrations of piperacillin and tazobactam were similar to those attained after the first dose due to the short half-lives of piperacillin and tazobactam.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Distribution</content>
                        </paragraph>
                        <paragraph>Both piperacillin and tazobactam are approximately 30% bound to plasma proteins. The protein binding of either piperacillin or tazobactam is unaffected by the presence of the other compound. Protein binding of the tazobactam metabolite is negligible.</paragraph>
                        <paragraph>Piperacillin and tazobactam are widely distributed into tissues and body fluids including intestinal mucosa, gallbladder, lung, female reproductive tissues (uterus, ovary, and fallopian tube), interstitial fluid, and bile. Mean tissue concentrations are generally 50% to 100% of those in plasma. Distribution of piperacillin and tazobactam into cerebrospinal fluid is low in subjects with non-inflamed meninges, as with other penicillins (see Table 8).</paragraph>
                        <table width="75%">
                           <caption>Table 8: Piperacillin/Tazobactam Concentrations in Selected Tissues and Fluids after Single 4 g/0.5 g 30-min IV Infusion of Piperacillin and Tazobactam for Injection</caption>
                           <tfoot>
                              <tr styleCode="First Last">
                                 <td colspan="7">
                                    <sup>a</sup> Each subject provided a single sample.<br/>
                                    <sup>b</sup> Time from the start of the infusion</td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center">
                                    <content styleCode="bold">Tissue or<br/> Fluid</content>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center">
                                    <content styleCode="bold"> N<sup>a</sup>
                                    </content>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center">
                                    <content styleCode="bold"> Sampling period<sup>b</sup>
                                       <br/> (h)</content>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center">
                                    <content styleCode="bold"> Mean PIP<br/> Concentration Range<br/> (mg/L)</content>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center">
                                    <content styleCode="bold"> Tissue:<br/> Plasma Range</content>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center">
                                    <content styleCode="bold">Tazo<br/> Concentration<br/> Range<br/> (mg/L)</content>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center">
                                    <content styleCode="bold"> Tazo Tissue:<br/> Plasma Range</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule">Skin</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center"> 35</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center"> 0.5 - 4.5</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center"> 34.8 - 94.2</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center"> 0.60 - 1.1</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center"> 4.0 - 7.7</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center"> 0.49 - 0.93</td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule">Fatty<br/>Tissue</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center"> 37</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center"> 0.5 - 4.5</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center"> 4.0 - 10.1</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center"> 0.097 - 0.115</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center"> 0.7 - 1.5</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center"> 0.10 - 0.13</td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule">Muscle</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center"> 36</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center"> 0.5 - 4.5</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center"> 9.4 - 23.3</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center"> 0.29 - 0.18</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center"> 1.4 - 2.7</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center"> 0.18 - 0.30</td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule">Proximal<br/> Intestinal<br/>Mucosa</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center"> 7</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center"> 1.5 - 2.5</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center"> 31.4</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center"> 0.55</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center"> 10.3</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center"> 1.15</td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule">Distal<br/>Intestinal<br/>Mucosa</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center"> 7</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center"> 1.5 - 2.5</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center"> 31.2</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center"> 0.59</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center"> 14.5</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center"> 2.1</td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule">Appendix</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center"> 22</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center"> 0.5 - 2.5</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center"> 26.5 - 64.1</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center"> 0.43 - 0.53</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center"> 9.1 - 18.6</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center"> 0.80 - 1.35</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>
                           <content styleCode="underline">Metabolism</content>
                        </paragraph>
                        <paragraph>Piperacillin is metabolized to a minor microbiologically active desethyl metabolite. Tazobactam is metabolized to a single metabolite that lacks pharmacological and antibacterial activities.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Excretion</content>
                        </paragraph>
                        <paragraph>Following single or multiple piperacillin and tazobactam for injection doses to healthy subjects, the plasma half-life of piperacillin and of tazobactam ranged from 0.7 to 1.2 hours and was unaffected by dose or duration of infusion.</paragraph>
                        <paragraph>Both piperacillin and tazobactam are eliminated via the kidney by glomerular filtration and tubular secretion. Piperacillin is excreted rapidly as unchanged drug with 68% of the administered dose excreted in the urine. Tazobactam and its metabolite are eliminated primarily by renal excretion with 80% of the administered dose excreted as unchanged drug and the remainder as the single metabolite. Piperacillin, tazobactam and desethyl piperacillin are also secreted into the bile.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Specific Populations</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Renal Impairment</content>
                        </paragraph>
                        <paragraph>After the administration of single doses of piperacillin/tazobactam to subjects with renal impairment, the half-life of piperacillin and of tazobactam increases with decreasing creatinine clearance. At creatinine clearance below 20 mL/min, the increase in half-life is twofold for piperacillin and fourfold for tazobactam compared to subjects with normal renal function. Dosage adjustments for piperacillin and tazobactam for injection are recommended when creatinine clearance is below 40 mL/min in patients receiving the usual recommended daily dose of piperacillin and tazobactam for injection. <content styleCode="italics">See Dosage and Administration (<linkHtml href="#Lf51ec41a-7f6c-4408-91f8-7f88e197eae3">2</linkHtml>)</content> for specific recommendations for the treatment of patients with renal-impairment.</paragraph>
                        <paragraph>Hemodialysis removes 30% to 40% of a piperacillin/tazobactam dose with an additional 5% of the tazobactam dose removed as the tazobactam metabolite. Peritoneal dialysis removes approximately 6% and 21% of the piperacillin and tazobactam doses, respectively, with up to 16% of the tazobactam dose removed as the tazobactam metabolite. For dosage recommendations for patients undergoing hemodialysis <content styleCode="italics">[</content>
                           <content styleCode="italics">see Dosage and Administration (<linkHtml href="#Lf51ec41a-7f6c-4408-91f8-7f88e197eae3">2</linkHtml>)</content>
                           <content styleCode="italics">]</content>.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Hepatic Impairment</content>
                        </paragraph>
                        <paragraph>The half-life of piperacillin and of tazobactam increases by approximately 25% and 18%, respectively, in patients with hepatic cirrhosis compared to healthy subjects. However, this difference does not warrant dosage adjustment of piperacillin and tazobactam for injection due to hepatic cirrhosis.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Pediatrics</content>
                        </paragraph>
                        <paragraph>Piperacillin and tazobactam pharmacokinetics were studied in pediatric patients 2 months of age and older. The clearance of both compounds is slower in the younger patients compared to older children and adults.</paragraph>
                        <paragraph>In a population PK analysis, estimated clearance for 9 month-old to 12 year-old patients was comparable to adults, with a population mean (SE) value of 5.64 (0.34) mL/min/kg. The piperacillin clearance estimate is 80% of this value for pediatric patients 2-9 months old. In patients younger than 2 months of age, clearance of piperacillin is slower compared to older children; however, it is not adequately characterized for dosing recommendations. The population mean (SE) for piperacillin volume of distribution is 0.243 (0.011) L/kg and is independent of age.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Geriatrics</content>
                        </paragraph>
                        <paragraph>The impact of age on the pharmacokinetics of piperacillin and tazobactam was evaluated in healthy male subjects, aged 18-35 years (n=6) and aged 65 to 80 years (n=12). Mean half-life for piperacillin and tazobactam was 32% and 55% higher, respectively, in the elderly compared to the younger subjects. This difference may be due to age-related changes in creatinine clearance.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Race</content>
                        </paragraph>
                        <paragraph>The effect of race on piperacillin and tazobactam was evaluated in healthy male volunteers. No difference in piperacillin or tazobactam pharmacokinetics was observed between Asian (n=9) and Caucasian (n=9) healthy volunteers who received single 4/0.5 g doses.</paragraph>
                        <paragraph>
                           <content styleCode="underline"> Drug Interactions</content>
                        </paragraph>
                        <paragraph>The potential for pharmacokinetic drug interactions between piperacillin and tazobactam for injection and aminoglycosides, probenecid, vancomycin, heparin, vecuronium, and methotrexate has been evaluated <content styleCode="italics">[</content>
                           <content styleCode="italics">see Drug Interactions</content>
                           <content styleCode="italics">
                              <linkHtml href="#L5ccd0173-4390-452d-b310-7b18e78d7e3c"> (7)</linkHtml>
                           </content>
                           <content styleCode="italics">]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20221031"/>
                  </section>
               </component>
               <component>
                  <section ID="L14ab85ab-6125-465b-bc62-4427fb8a23a2">
                     <id root="093c8600-7e35-4699-b8df-57cddca88020"/>
                     <code code="49489-8" displayName="MICROBIOLOGY SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>12.4 Microbiology</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Mechanism of Action</content>
                        </paragraph>
                        <paragraph>Piperacillin sodium exerts bactericidal activity by inhibiting septum formation and cell wall synthesis of susceptible bacteria. In vitro, piperacillin is active against a variety of gram-positive and gram-negative aerobic and anaerobic bacteria. Tazobactam sodium has little clinically relevant in vitro activity against bacteria due to its reduced affinity to penicillin-binding proteins. It is, however, a beta-lactamase inhibitor of the Molecular Class A enzymes, including Richmond-Sykes Class III (Bush class 2b &amp; 2b') penicillinases and cephalosporinases. It varies in its ability to inhibit class II and IV (2a &amp; 4) penicillinases. Tazobactam does not induce chromosomally-mediated beta-lactamases at tazobactam concentrations achieved with the recommended dosage regimen.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Antimicrobial Activity</content>
                        </paragraph>
                        <paragraph>Piperacillin and tazobactam for injection has been shown to be active against most isolates of the following microorganisms, both in vitro and in clinical infections [<content styleCode="italics">see Indications and Usage (<linkHtml href="#L1ed3ac46-8cd0-4988-bcc1-29d228daaa62">1</linkHtml>)</content>]:</paragraph>
                        <paragraph/>
                        <paragraph>   Aerobic bacteria<br/>      Gram-positive bacteria:<br/>
                           <content styleCode="italics">      Staphylococcus aureus</content> (methicillin susceptible isolates only)</paragraph>
                        <paragraph>
                           <br/>      Gram-negative bacteria:<br/>
                           <content styleCode="italics">      Acinetobacter baumannii</content>
                           <br/>
                           <content styleCode="italics">      Escherichia coli</content>
                           <br/>
                           <content styleCode="italics">      Haemophilus influenzae</content> (excluding beta-lactamase negative, ampicillin-resistant isolates)<br/>
                           <content styleCode="italics">      Klebsiella pneumoniae</content>
                           <br/>
                           <content styleCode="italics">      Pseudomonas aeruginosa</content> (given in combination with an aminoglycoside to which the isolate is susceptible)</paragraph>
                        <paragraph>
                           <br/>   Anaerobic bacteria:<br/>
                           <content styleCode="italics">      Bacteroides fragilis</content> group (<content styleCode="italics">B. fragilis</content>, <content styleCode="italics">B. ovatus</content>, <content styleCode="italics">B. thetaiotaomicron</content>, and <content styleCode="italics">B. vulgatus</content>)</paragraph>
                        <paragraph>The following in vitro data are available, but their clinical significance is unknown. At least 90 percent of the following bacteria exhibit an in vitro minimum inhibitory concentration (MIC) less than or equal to the susceptible breakpoint for piperacillin/tazobactam against isolates of similar genus or organism group. However, the efficacy of piperacillin and tazobactam in treating clinical infections caused by these bacteria has not been established in adequate and well-controlled clinical trials.</paragraph>
                        <paragraph>
                           <br/>   Aerobic bacteria<br/>      Gram-positive bacteria<br/>
                           <content styleCode="italics">      Enterococcus faecalis</content> (ampicillin or penicillin-susceptible isolates only)<br/>
                           <content styleCode="italics">      Staphylococcus epidermidis</content> (methicillin susceptible isolates only)<br/>
                           <content styleCode="italics">      Streptococcus agalactiae</content>
                           <sup>†</sup>
                           <br/>
                           <content styleCode="italics">      Streptococcus pneumoniae</content>
                           <sup>†</sup> (penicillin-susceptible isolates only)<br/>
                           <content styleCode="italics">      Streptococcus pyogenes</content>
                           <sup>†</sup>
                           <br/>      Viridans group streptococci<sup>†</sup>
                        </paragraph>
                        <paragraph>      Gram-negative bacteria<br/>
                           <content styleCode="italics">      Citrobacter koseri</content>
                           <br/>
                           <content styleCode="italics">      Moraxella catarrhalis</content>
                           <br/>
                           <content styleCode="italics">      Morganella morganii</content>
                           <br/>
                           <content styleCode="italics">      Neisseria gonorrhoeae</content>
                           <br/>
                           <content styleCode="italics">      Proteus mirabilis</content>
                           <br/>
                           <content styleCode="italics">      Proteus vulgaris</content>
                           <br/>
                           <content styleCode="italics">      Serratia marcescens</content>
                           <br/>
                           <content styleCode="italics">      Providencia stuartii</content>
                           <br/>
                           <content styleCode="italics">      Providencia rettgeri</content>
                           <br/>
                           <content styleCode="italics">      Salmonella enterica</content>
                        </paragraph>
                        <paragraph>   Anaerobic bacteria<br/>
                           <content styleCode="italics">      Clostridium perfringens</content>
                           <br/>
                           <content styleCode="italics">      Bacteroides distasonis</content>
                           <br/>
                           <content styleCode="italics">      Prevotella melaninogenica</content>
                        </paragraph>
                        <paragraph>
                           <sup>†</sup>These are not beta-lactamase producing bacteria and, therefore, are susceptible to piperacillin alone.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Susceptibility Testing</content>
                        </paragraph>
                        <paragraph>For specific information regarding susceptibility test interpretive criteria, and associated test methods and quality control standards recognized by FDA for this drug, please see: <content styleCode="underline">
                              <linkHtml href="https://www.fda.gov/STIC">https://www.fda.gov/STIC</linkHtml>
                           </content>.</paragraph>
                     </text>
                     <effectiveTime value="20240916"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="L29aad391-7826-4489-8045-aa3bd08bf4de">
               <id root="d18a936e-a3c6-4bbe-bf46-e7bb78b87b0b"/>
               <code code="43680-8" displayName="NONCLINICAL TOXICOLOGY SECTION" codeSystem="2.16.840.1.113883.6.1"/>
               <title>13 NONCLINICAL TOXICOLOGY</title>
               <text/>
               <effectiveTime value="20221031"/>
               <component>
                  <section ID="L43bf3a86-67fc-45f3-80d5-c9687209ed08">
                     <id root="4dacb9b7-0135-48a1-a46d-b0000586a747"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Carcinogenesis</content>
                           <br/>Long-term carcinogenicity studies in animals have not been conducted with piperacillin/tazobactam, piperacillin, or tazobactam.<br/>
                        </paragraph>
                        <paragraph>
                           <content styleCode="underline">Mutagenesis</content>
                           <br/>Piperacillin/tazobactam was negative in microbial mutagenicity assays, the unscheduled DNA synthesis (UDS) test, a mammalian point mutation (Chinese hamster ovary cell HPRT) assay, and a mammalian cell (BALB/c-3T3) transformation assay. <content styleCode="italics">In vivo</content>, piperacillin/tazobactam did not induce chromosomal aberrations in rats.<br/>
                        </paragraph>
                        <paragraph>
                           <content styleCode="underline">Fertility</content>
                           <br/>Reproduction studies have been performed in rats and have revealed no evidence of impaired fertility when piperacillin/tazobactam is administered intravenously up to a dose of 1280/320 mg/kg piperacillin/tazobactam, which is similar to the maximum recommended human daily dose based on body-surface area (mg/m<sup>2</sup>).</paragraph>
                     </text>
                     <effectiveTime value="20221031"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="Lc988e42f-47ca-4ce7-a581-10bb676b6a0e">
               <id root="99bb8170-fe50-4c24-b599-f3019227d392"/>
               <code code="34093-5" displayName="REFERENCES SECTION" codeSystem="2.16.840.1.113883.6.1"/>
               <title>15 REFERENCES</title>
               <text>
                  <paragraph>1. Jensen J-US, Hein L, Lundgren B, et al. BMJ Open 2012; 2:e000635. doi:10.1136.</paragraph>
               </text>
               <effectiveTime value="20221031"/>
            </section>
         </component>
         <component>
            <section ID="L46fa625e-c7e2-4132-9893-253489c9b40f">
               <id root="96f11387-94cf-4bb0-8079-3dde5e422929"/>
               <code code="34069-5" displayName="HOW SUPPLIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
               <title>16 HOW SUPPLIED/STORAGE AND HANDLING</title>
               <text>
                  <paragraph>Piperacillin and Tazobactam for Injection, USP are supplied as pharmacy bulk bottles in the following size:</paragraph>
                  <list listType="unordered">
                     <item>Each Piperacillin and Tazobactam for Injection, USP 13.5 g pharmacy bulk bottle provides piperacillin sodium equivalent to 12 grams of piperacillin and tazobactam sodium equivalent to 1.5 g tazobactam. Each bottle contains 29.16 mEq (672 mg) of sodium. Supplied as singles-NDC 81284-154-01 or 10 per box-NDC 81284-154-10.</item>
                     <item>Each Piperacillin and Tazobactam for Injection, USP 40.5 g pharmacy bulk bottle provides piperacillin sodium equivalent to 36 grams of piperacillin and tazobactam sodium equivalent to 4.5 grams of tazobactam. Each pharmacy bulk bottle contains 87.48 mEq (2016 mg) of sodium. NDC 81284-155-01.</item>
                  </list>
                  <paragraph>Piperacillin and Tazobactam for Injection, USP pharmacy bulk bottles should be stored at controlled room temperature (20°C to 25°C [68°F to 77°F]) prior to reconstitution.</paragraph>
               </text>
               <effectiveTime value="20221031"/>
            </section>
         </component>
         <component>
            <section ID="L4a6a7f2f-873c-4f5a-88af-6e87f862ce2b">
               <id root="b0883963-4c5d-4af1-910a-7c43159a45da"/>
               <code code="34076-0" displayName="INFORMATION FOR PATIENTS SECTION" codeSystem="2.16.840.1.113883.6.1"/>
               <title>17 PATIENT COUNSELING INFORMATION</title>
               <text/>
               <effectiveTime value="20240916"/>
               <component>
                  <section ID="L787b99f7-b137-40a8-92df-a1f10dcf79aa">
                     <id root="351db912-923a-4179-8fa9-436f04779ce0"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Serious Hypersensitivity Reactions</content>
                        </paragraph>
                        <paragraph>Advise patients, their families, or caregivers that serious hypersensitivity reactions, including serious allergic cutaneous reactions, could occur with use of piperacillin and tazobactam for injection that require immediate treatment. Ask them about any previous hypersensitivity reactions to piperacillin and tazobactam for injection, other beta-lactams (including cephalosporins), or other allergens <content styleCode="italics">[</content>
                           <content styleCode="italics">see Warnings and Precautions (<linkHtml href="#L4324d4bb-273f-49fb-ba18-f3c3de384515">5.2</linkHtml>)</content>
                           <content styleCode="italics">]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20240916"/>
                  </section>
               </component>
               <component>
                  <section ID="L97124b29-b930-4f7a-b2e0-35818435b0fc">
                     <id root="a5dd2965-c247-4c21-b16a-3b5bde4149b1"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Hemophagocytic Lymphohistiocytosis</content>
                        </paragraph>
                        <paragraph>Prior to initiation of treatment with piperacillin and tazobactam for injection, inform patients that excessive immune activation may occur with piperacillin and tazobactam for injection and that they should report signs or symptoms such as fever, rash, or lymphadenopathy to a healthcare provider immediately <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#Lb38164a3-89ff-4552-a153-71e46e87cd5b">5.3</linkHtml>)]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20221031"/>
                  </section>
               </component>
               <component>
                  <section ID="Lc31a2581-7f7d-4778-bbcd-26f4d9a90269">
                     <id root="62f6cebc-164c-45d4-82fe-4072b103344e"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Diarrhea</content>
                        </paragraph>
                        <paragraph>Advise patients, their families, or caregivers that diarrhea is a common problem caused by antibacterial drugs, including piperacillin and tazobactam for injection, which usually ends when the drug is discontinued. Sometimes after starting treatment with antibacterial drugs, patients can develop watery and bloody stools (with or without stomach cramps and fever) even as late as two or more months after having taken the last dose of the drug. If this occurs, patients should contact their physician as soon as possible <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#Lc6a19e90-286b-4ee8-8070-09f051adf5f7">5.9</linkHtml>)]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20240916"/>
                  </section>
               </component>
               <component>
                  <section ID="L927a7342-ef47-447a-9aca-bfbddb5ca3d2">
                     <id root="fc865f8a-8a18-4808-84b2-e2449d228d59"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Antibacterial Resistance</content>
                        </paragraph>
                        <paragraph>Patients should be counseled that antibacterial drugs including piperacillin and tazobactam for injection should only be used to treat bacterial infections. They do not treat viral infections (e.g., the common cold). When piperacillin and tazobactam for injection is prescribed to treat a bacterial infection, patients should be told that although it is common to feel better early in the course of therapy, the medication should be taken exactly as directed. Skipping doses or not completing the full course of therapy may (1) decrease the effectiveness of the immediate treatment and (2) increase the likelihood that bacteria will develop resistance and will not be treatable by piperacillin and tazobactam for injection or other antibacterial drugs in the future.</paragraph>
                        <paragraph>Counsel patients that piperacillin and tazobactam for injection can cross the placenta in humans and is excreted in human milk.</paragraph>
                     </text>
                     <effectiveTime value="20221031"/>
                  </section>
               </component>
               <component>
                  <section ID="L59f454dd-3cd0-46c1-b6cf-0616e1624656">
                     <id root="df90edf4-b075-4041-8d55-d4853b9eee8a"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Pregnancy and Lactation</content>
                        </paragraph>
                        <paragraph>Patients should be counseled that piperacillin and tazobactam for injection can cross the placenta in humans and is excreted in human milk <content styleCode="italics">[see Use in Specific Populations (<linkHtml href="#L675a98d8-e68f-43e6-bf1a-09f6eb19ec9c">8.1</linkHtml>, <linkHtml href="#Lcd8c05dc-f3ca-44e4-b3a7-5d572c30da75">8.2</linkHtml>)]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20221031"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="L1114235e-c2de-4f5e-ba89-b94b7549009f">
               <id root="ae936f1e-6fb9-4b2b-9878-d9af19b80b31"/>
               <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
               <text>
                  <paragraph>
                     <content styleCode="bold">Manufactured for:</content>
                  </paragraph>
                  <paragraph>Provepharm SAS</paragraph>
                  <paragraph>
                     <content styleCode="bold">Distributed by:</content>
                     <br/>Provepharm, Inc.<br/>Collegeville, PA 19426<renderMultiMedia referencedObject="L7817b14b-70c8-499d-974b-929706a17488"/>
                  </paragraph>
                  <paragraph>Made in Italy</paragraph>
                  <paragraph>Revised 11/2024</paragraph>
               </text>
               <effectiveTime value="20241231"/>
               <component>
                  <observationMedia ID="L7817b14b-70c8-499d-974b-929706a17488">
                     <text>provepharm</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="provepharm.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="L183f53be-b1f2-4c52-9b2f-0558cfb117b5">
               <id root="cf5cd1a7-fd40-4ab7-8cd8-1f8451514219"/>
               <code code="51945-4" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL" codeSystem="2.16.840.1.113883.6.1"/>
               <title>
                  <content styleCode="bold">PRINCIPAL DISPLAY PANEL - 40.5 GRAMS PHARMACY BULK PACKAGE</content>
               </title>
               <text>
                  <paragraph>NDC 81284-<content styleCode="bold">155</content>-00 Rx only</paragraph>
                  <paragraph>
                     <content styleCode="bold">Piperacillin and Tazobactam for Injection, USP</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">40.5 grams per Pharmacy Bulk Package</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">For Intravenous Use Only </content>Sterile</paragraph>
                  <paragraph>
                     <content styleCode="bold">Preservative Free</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Pharmacy Bulk Package — Not for Direct Infusion</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">RECONSTITUTED STOCK SOLUTION MUST BE TRANSFERRED AND FURTHER DILUTED FOR INTRAVENOUS INFUSION</content>
                  </paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="L90b21830-f29c-497f-a511-2a0f578d7686"/>
                  </paragraph>
               </text>
               <effectiveTime value="20200131"/>
               <component>
                  <observationMedia ID="L90b21830-f29c-497f-a511-2a0f578d7686">
                     <text>piptazo40b</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="piptazo40b.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="L9ccf9de9-4167-4c3a-a6b0-96a51fcca5b4">
               <id root="fc8c9836-8b65-446d-82a2-d825d0c3decc"/>
               <code code="51945-4" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL" codeSystem="2.16.840.1.113883.6.1"/>
               <title>
                  <content styleCode="bold">PRINCIPAL DISPLAY PANEL - 40.5 GRAMS PHARMACY BULK PACKAGE (CARTON)</content>
               </title>
               <text>
                  <paragraph>
                     <renderMultiMedia referencedObject="Lbe38de0e-83f4-42e7-9ae5-b8505af868fe"/>
                  </paragraph>
               </text>
               <effectiveTime value="20200131"/>
               <component>
                  <observationMedia ID="Lbe38de0e-83f4-42e7-9ae5-b8505af868fe">
                     <text>piptazo40c</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="piptazo40c.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="L153bb701-e719-4db5-8ac0-f8bbed7c5b3d">
               <id root="afb6830e-6a7e-4e47-9799-8a322b79ae37"/>
               <code code="51945-4" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL" codeSystem="2.16.840.1.113883.6.1"/>
               <title>
                  <content styleCode="bold">PRINCIPAL DISPLAY PANEL - 13.5 GRAMS PHARMACY BULK PACKAGE</content>
               </title>
               <text>
                  <paragraph>NDC 81284-<content styleCode="bold">154</content>-00 Rx only</paragraph>
                  <paragraph>
                     <content styleCode="bold">Piperacillin and Tazobactam for Injection, USP</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">13.5 grams per Pharmacy Bulk Package</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">For Intravenous Use Only - </content>Sterile</paragraph>
                  <paragraph>
                     <content styleCode="bold">Preservative Free</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Pharmacy Bulk Package — Not for Direct Infusion</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">RECONSTITUTED STOCK SOLUTION MUST BE TRANSFERRED AND FURTHER DILUTED FOR INTRAVENOUS INFUSION</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">
                        <renderMultiMedia referencedObject="L90b21830-f29c-497f-a511-2a0f578d8888"/>
                     </content>
                  </paragraph>
               </text>
               <effectiveTime value="20200131"/>
               <component>
                  <observationMedia ID="L90b21830-f29c-497f-a511-2a0f578d8888">
                     <text>piptazo13b</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="piptazo13b.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="Led055c56-880d-4899-b73f-187db76ab54c">
               <id root="aa9a5ae5-75b0-4c47-b6f3-ec845178eec9"/>
               <code code="51945-4" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL" codeSystem="2.16.840.1.113883.6.1"/>
               <title>
                  <content styleCode="bold">PRINCIPAL DISPLAY PANEL - 13.5 GRAMS PHARMACY BULK PACKAGE (CARTON)</content>
               </title>
               <text>
                  <paragraph>
                     <renderMultiMedia referencedObject="Lbe38de0e-83f4-42e7-9ae5-b8505af89999"/>
                  </paragraph>
               </text>
               <effectiveTime value="20221031"/>
               <component>
                  <observationMedia ID="Lbe38de0e-83f4-42e7-9ae5-b8505af89999">
                     <text>piptazo13c</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="piptazo13c.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>